Author: "Petronio Anna" / Database: OAIster - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Petronio Anna"' showing total 63 results

Start Over Author "Petronio Anna" Database OAIster

63 results on '"Petronio Anna"'

1. Incidence, Predictors, and Outcomes of Paravalvular Regurgitation after TAVR in Sievers Type-1 Bicuspid Aortic Valves

Author: Zito, Andrea, Buono, Andrea, Scotti, Andrea, Kim, Won-Keun, Fabris, Tommaso, de Biase, Chiara, Bellamoli, Michele, Montarello, Nichola, Costa, Giuliano, Alfadhel, Mesfer, Koren, Ofir, Fezzi, Simone, Bellini, Barbara, Massussi, Mauro, Bai, Lin, Costa, Giulia, Mazzapicchi, Alessandro, Giacomin, Enrico, Gorla, Riccardo, Hug, Karsten, Briguori, Carlo, Bettari, Luca, Messina, Antonio, Villa, Emmanuel, Boiago, Mauro, Romagnoli, Enrico, Orbach, Ady, Laterra, Giulia, Aurigemma, Cristina, De Carlo, Marco, Renker, Matthia, Gomez, Mario Garcia, Trani, Carlo, Ielasi, Alfonso, Landes, Uri, Rheude, Tobia, Testa, Luca, Santos, Ignacio Amat, Mangieri, Antonio, Saia, Francesco, Favero, Luca, Chen, Mao, Adamo, Marianna, Petronio, Anna Sonia, Montorfano, Matteo, Makkar, Raj R, Mylotte, Darren, Blackman, Daniel J, Barbanti, Marco, De Backer, Ole, Tchètchè, Didier, Tarantini, Giuseppe, Latib, Azeem, Maffeo, Diego, Burzotta, Francesco, Trani, Carlo (ORCID:0000-0001-9777-013X), Burzotta, Francesco (ORCID:0000-0002-6569-9401), Zito, Andrea, Buono, Andrea, Scotti, Andrea, Kim, Won-Keun, Fabris, Tommaso, de Biase, Chiara, Bellamoli, Michele, Montarello, Nichola, Costa, Giuliano, Alfadhel, Mesfer, Koren, Ofir, Fezzi, Simone, Bellini, Barbara, Massussi, Mauro, Bai, Lin, Costa, Giulia, Mazzapicchi, Alessandro, Giacomin, Enrico, Gorla, Riccardo, Hug, Karsten, Briguori, Carlo, Bettari, Luca, Messina, Antonio, Villa, Emmanuel, Boiago, Mauro, Romagnoli, Enrico, Orbach, Ady, Laterra, Giulia, Aurigemma, Cristina, De Carlo, Marco, Renker, Matthia, Gomez, Mario Garcia, Trani, Carlo, Ielasi, Alfonso, Landes, Uri, Rheude, Tobia, Testa, Luca, Santos, Ignacio Amat, Mangieri, Antonio, Saia, Francesco, Favero, Luca, Chen, Mao, Adamo, Marianna, Petronio, Anna Sonia, Montorfano, Matteo, Makkar, Raj R, Mylotte, Darren, Blackman, Daniel J, Barbanti, Marco, De Backer, Ole, Tchètchè, Didier, Tarantini, Giuseppe, Latib, Azeem, Maffeo, Diego, Burzotta, Francesco, Trani, Carlo (ORCID:0000-0001-9777-013X), and Burzotta, Francesco (ORCID:0000-0002-6569-9401)
Abstract: Background: Transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic valve (BAV) stenosis is technically challenging and is burdened by an increased risk of paravalvular regurgitation (PVR). Objectives: To identify the incidence, predictors, and clinical outcomes of PVR following TAVR in Sievers type 1 BAV stenosis. Methods: Consecutive patients with severe Sievers type 1 BAV stenosis undergoing TAVR with current generation transcatheter heart valves (THVs) in 24 international centres were enrolled. PVR was graded as none/trace, mild, moderate, and severe according to echocardiographic criteria. The endpoint of major adverse events (MAE), defined as a composite of all-cause death, stroke, or hospitalization for heart failure, was assessed at the last available follow-up. Results: A total of 946 patients were enrolled. PVR occurred in 423 patients (44.7%): mild, moderate, and severe in 387 (40.9%), 32 (3.4%), and 4 (0.4%) patients, respectively. Independent predictors of moderate or severe PVR were larger virtual raphe ring (VRR) perimeter (ORadj 1.07, 95% CI 1.02-1.13), severe annular or left ventricular outflow tract (LVOT) calcification (ORadj 5.21, 95% CI 1.45-18.77), self-expanding valve (ORadj 9.01, 95% CI 2.09-38.86), and intentional supra-annular THV positioning (ORadj 3.31, 95% CI 1.04-10.54). At a median follow-up of 1.3 [IQR 0.5-2.4] years, moderate or severe PVR was associated with an increased risk of MAE (HRadj 2.52, 95% CI 1.24-5.09). Conclusions: After TAVR with current-generation THVs in Sievers type 1 BAV stenosis, moderate or severe PVR occurred in about 4% of cases and was associated with an increased risk of MAE during follow-up.
Published: 2024

2. Data standards for transcatheter aortic valve implantation : the European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart).

Author: Aktaa, Suleman, Batra, Gorav, James, Stefan, Blackman, Daniel J, Ludman, Peter F, Mamas, Mamas A, Abdel-Wahab, Mohamed, Angelini, Gianni D, Czerny, Martin, Delgado, Victoria, De Luca, Giuseppe, Eustachio, Agricola, Foldager, Dan, Hamm, Christian W, Iung, Bernard, Mangner, Norman, Mehilli, Julinda, Murphy, Gavin J, Mylotte, Darren, Parma, Radoslaw, Petronio, Anna Sonia, Popescu, Bodgan A, Sondergaard, Lars, Teles, Rui C, Sabaté, Manel, Terkelsen, Christian J, Testa, Luca, Wu, Jianhua, Maggioni, Aldo P, Wallentin, Lars, Casadei, Barbara, Gale, Chris P, Aktaa, Suleman, Batra, Gorav, James, Stefan, Blackman, Daniel J, Ludman, Peter F, Mamas, Mamas A, Abdel-Wahab, Mohamed, Angelini, Gianni D, Czerny, Martin, Delgado, Victoria, De Luca, Giuseppe, Eustachio, Agricola, Foldager, Dan, Hamm, Christian W, Iung, Bernard, Mangner, Norman, Mehilli, Julinda, Murphy, Gavin J, Mylotte, Darren, Parma, Radoslaw, Petronio, Anna Sonia, Popescu, Bodgan A, Sondergaard, Lars, Teles, Rui C, Sabaté, Manel, Terkelsen, Christian J, Testa, Luca, Wu, Jianhua, Maggioni, Aldo P, Wallentin, Lars, Casadei, Barbara, and Gale, Chris P
Abstract: AIMS: Standardized data definitions are necessary for the quantification of quality of care and patient outcomes in observational studies and randomised controlled trials (RCTs). The European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart) project of the European Society of Cardiology (ESC) aims to create pan-European data standards for cardiovascular diseases and interventions, including transcatheter aortic valve implantation (TAVI). METHODS AND RESULTS: We followed the EuroHeart methodology for cardiovascular data standard development. A Working Group of 29 members representing 12 countries was established and included a patient representative, as well as experts in the management of valvular heart disease from the European Association of Percutaneous Cardiovascular Interventions (EAPCI), the European Association of Cardiovascular Imaging (EACVI) and the Working Group on Cardiovascular Surgery. We conducted a systematic review of the literature and used a modified Delphi method to reach consensus on a final set of variables. For each variable, the Working Group provided a definition, permissible values and categorized the variable as mandatory (Level 1) or additional (Level 2) based on its clinical importance and feasibility. In total, 93 Level 1 and 113 Level 2 variables were selected, with the level 1 variables providing the dataset for registration of patients undergoing TAVI on the EuroHeart IT platform. CONCLUSION: This document provides details of the EuroHeart data standards for TAVI processes of care and in-hospital outcomes. In the context of EuroHeart, this will facilitate quality improvement, observational research, registry-based RCTs and post-marketing surveillance of devices and pharmacotherapies.
Published: 2023
Full Text: View/download PDF

3. Transcatheter Mitral Valve Replacement Versus Medical Therapy for Secondary Mitral Regurgitation:A Propensity Score-Matched Comparison

Author: Ludwig, Sebastian, Conradi, Lenard, Cohen, David J., Coisne, Augustin, Scotti, Andrea, Abraham, William T., Ben Ali, Walid, Zhou, Zhipeng, Li, Yanru, Kar, Saibal, Duncan, Alison, Scott Lim, D., Adamo, Marianna, Redfors, Björn, Muller, David W.M., Webb, John G., Petronio, Anna S., Ruge, Hendrik, Nickenig, Georg, Sondergaard, Lars, Adam, Matti, Regazzoli, Damiano, Garatti, Andrea, Schmidt, Tobias, Andreas, Martin, Dahle, Gry, Walther, Thomas, Kempfert, Joerg, Tang, Gilbert H.L., Redwood, Simon, Taramasso, Maurizio, Praz, Fabien, Fam, Neil, Dumonteil, Nicolas, Obadia, Jean François, Von Bardeleben, Ralph Stephan, Rudolph, Tanja K., Reardon, Michael J., Metra, Marco, Denti, Paolo, Mack, Michael J., Hausleiter, Jörg, Asch, Federico M., Latib, Azeem, Lindenfeld, Joann, Modine, Thomas, Stone, Gregg W., Granada, Juan F., Ludwig, Sebastian, Conradi, Lenard, Cohen, David J., Coisne, Augustin, Scotti, Andrea, Abraham, William T., Ben Ali, Walid, Zhou, Zhipeng, Li, Yanru, Kar, Saibal, Duncan, Alison, Scott Lim, D., Adamo, Marianna, Redfors, Björn, Muller, David W.M., Webb, John G., Petronio, Anna S., Ruge, Hendrik, Nickenig, Georg, Sondergaard, Lars, Adam, Matti, Regazzoli, Damiano, Garatti, Andrea, Schmidt, Tobias, Andreas, Martin, Dahle, Gry, Walther, Thomas, Kempfert, Joerg, Tang, Gilbert H.L., Redwood, Simon, Taramasso, Maurizio, Praz, Fabien, Fam, Neil, Dumonteil, Nicolas, Obadia, Jean François, Von Bardeleben, Ralph Stephan, Rudolph, Tanja K., Reardon, Michael J., Metra, Marco, Denti, Paolo, Mack, Michael J., Hausleiter, Jörg, Asch, Federico M., Latib, Azeem, Lindenfeld, Joann, Modine, Thomas, Stone, Gregg W., and Granada, Juan F.
Abstract: Background: Transcatheter mitral valve replacement (TMVR) is an emerging therapeutic alternative for patients with secondary mitral regurgitation (MR). Outcomes of TMVR versus guideline-directed medical therapy (GDMT) have not been investigated for this population. This study aimed to compare clinical outcomes of patients with secondary MR undergoing TMVR versus GDMT alone. Methods: The CHOICE-MI registry (Choice of Optimal Transcatheter Treatment for Mitral Insufficiency) included patients with MR undergoing TMVR using dedicated devices. Patients with MR pathogeneses other than secondary MR were excluded. Patients treated with GDMT alone were derived from the control arm of the COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation). We compared outcomes between the TMVR and GDMT groups, using propensity score matching to adjust for baseline differences. Results: After propensity score matching, 97 patient pairs undergoing TMVR (72.9±8.7 years; 60.8% men; transapical access, 91.8%) versus GDMT (73.1±11.0 years; 59.8% men) were compared. At 1 and 2 years, residual MR was ≤1+ in all patients of the TMVR group compared with 6.9% and 7.7%, respectively, in those receiving GDMT alone (both P<0.001). The 2-year rate of heart failure hospitalization was significantly lower in the TMVR group (32.8% versus 54.4%; hazard ratio, 0.59 [95% CI, 0.35–0.99]; P=0.04). Among survivors, a higher proportion of patients were in the New York Heart Association functional class I or II in the TMVR group at 1 year (78.2% versus 59.7%; P=0.03) and at 2 years (77.8% versus 53.2%; P=0.09). Two-year mortality was similar in the 2 groups (TMVR versus GDMT, 36.8% versus 40.8%; hazard ratio, 1.01 [95% CI, 0.62–1.64]; P=0.98). Conclusions: In this observational comparison, over 2-year follow-up, TMVR using mostly transapical devices in patients with secondar, Background: Transcatheter mitral valve replacement (TMVR) is an emerging therapeutic alternative for patients with secondary mitral regurgitation (MR). Outcomes of TMVR versus guideline-directed medical therapy (GDMT) have not been investigated for this population. This study aimed to compare clinical outcomes of patients with secondary MR undergoing TMVR versus GDMT alone. Methods: The CHOICE-MI registry (Choice of Optimal Transcatheter Treatment for Mitral Insufficiency) included patients with MR undergoing TMVR using dedicated devices. Patients with MR pathogeneses other than secondary MR were excluded. Patients treated with GDMT alone were derived from the control arm of the COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation). We compared outcomes between the TMVR and GDMT groups, using propensity score matching to adjust for baseline differences. Results: After propensity score matching, 97 patient pairs undergoing TMVR (72.9±8.7 years; 60.8% men; transapical access, 91.8%) versus GDMT (73.1±11.0 years; 59.8% men) were compared. At 1 and 2 years, residual MR was ≤1+ in all patients of the TMVR group compared with 6.9% and 7.7%, respectively, in those receiving GDMT alone (both P<0.001). The 2-year rate of heart failure hospitalization was significantly lower in the TMVR group (32.8% versus 54.4%; hazard ratio, 0.59 [95% CI, 0.35-0.99]; P=0.04). Among survivors, a higher proportion of patients were in the New York Heart Association functional class I or II in the TMVR group at 1 year (78.2% versus 59.7%; P=0.03) and at 2 years (77.8% versus 53.2%; P=0.09). Two-year mortality was similar in the 2 groups (TMVR versus GDMT, 36.8% versus 40.8%; hazard ratio, 1.01 [95% CI, 0.62-1.64]; P=0.98). Conclusions: In this observational comparison, over 2-year follow-up, TMVR using mostly transapical devices in patients with secondary MR was associated with significant red
Published: 2023

4. Vascular Access in Patients With Peripheral Arterial Disease Undergoing TAVR: The Hostile Registry

Author: Palmerini, Tullio, Saia, Francesco, Kim, Won-Keun, Renker, Matthia, Iadanza, Alessandro, Fineschi, Massimo, Bruno, Antonio Giulio, Ghetti, Gabriele, Vanhaverbeke, Maarten, Søndergaard, Lar, De Backer, Ole, Romagnoli, Enrico, Burzotta, Francesco, Trani, Carlo, Adrichem, Rik, Van Mieghem, Nicolas M, Nardi, Elena, Chietera, Francesco, Orzalkiewicz, Mateusz, Tomii, Daijiro, Pilgrim, Thoma, Aranzulla, Tiziana Claudia, Musumeci, Giuseppe, Adam, Matti, Meertens, Max M, Taglieri, Nevio, Marrozzini, Cinzia, Alvarez Covarrubias, Hector Alfonso, Joner, Michael, Nardi, Giulia, Di Muro, Francesca Maria, Di Mario, Carlo, Loretz, Lucca, Toggweiler, Stefan, Gallitto, Enrico, Gargiulo, Mauro, Testa, Luca, Bedogni, Francesco, Berti, Sergio, Ancona, Marco B, Montorfano, Matteo, Leone, Alessandro, Savini, Carlo, Pacini, Davide, Gmeiner, Jona, Braun, Daniel, Nerla, Roberto, Castriota, Fausto, De Carlo, Marco, Petronio, Anna Sonia, Barbanti, Marco, Costa, Giuliano, Tamburino, Corrado, Leone, Pier Pasquale, Reimers, Bernhard, Stefanini, Giulio, Sudo, Mitsumasa, Nickenig, Georg, Piva, Tommaso, Scotti, Andrea, Latib, Azeem, Vercellino, Matteo, Porto, Italo, Codner, Pablo, Kornowski, Ran, Bartorelli, Antonio L, Tarantini, Giuseppe, Fraccaro, Chiara, Abdel-Wahab, Mohamed, Grube, Eberhard, Galié, Nazzareno, Stone, Gregg W, Burzotta, Francesco (ORCID:0000-0002-6569-9401), Trani, Carlo (ORCID:0000-0001-9777-013X), Porto, Italo (ORCID:0000-0002-9854-5046), Palmerini, Tullio, Saia, Francesco, Kim, Won-Keun, Renker, Matthia, Iadanza, Alessandro, Fineschi, Massimo, Bruno, Antonio Giulio, Ghetti, Gabriele, Vanhaverbeke, Maarten, Søndergaard, Lar, De Backer, Ole, Romagnoli, Enrico, Burzotta, Francesco, Trani, Carlo, Adrichem, Rik, Van Mieghem, Nicolas M, Nardi, Elena, Chietera, Francesco, Orzalkiewicz, Mateusz, Tomii, Daijiro, Pilgrim, Thoma, Aranzulla, Tiziana Claudia, Musumeci, Giuseppe, Adam, Matti, Meertens, Max M, Taglieri, Nevio, Marrozzini, Cinzia, Alvarez Covarrubias, Hector Alfonso, Joner, Michael, Nardi, Giulia, Di Muro, Francesca Maria, Di Mario, Carlo, Loretz, Lucca, Toggweiler, Stefan, Gallitto, Enrico, Gargiulo, Mauro, Testa, Luca, Bedogni, Francesco, Berti, Sergio, Ancona, Marco B, Montorfano, Matteo, Leone, Alessandro, Savini, Carlo, Pacini, Davide, Gmeiner, Jona, Braun, Daniel, Nerla, Roberto, Castriota, Fausto, De Carlo, Marco, Petronio, Anna Sonia, Barbanti, Marco, Costa, Giuliano, Tamburino, Corrado, Leone, Pier Pasquale, Reimers, Bernhard, Stefanini, Giulio, Sudo, Mitsumasa, Nickenig, Georg, Piva, Tommaso, Scotti, Andrea, Latib, Azeem, Vercellino, Matteo, Porto, Italo, Codner, Pablo, Kornowski, Ran, Bartorelli, Antonio L, Tarantini, Giuseppe, Fraccaro, Chiara, Abdel-Wahab, Mohamed, Grube, Eberhard, Galié, Nazzareno, Stone, Gregg W, Burzotta, Francesco (ORCID:0000-0002-6569-9401), Trani, Carlo (ORCID:0000-0001-9777-013X), and Porto, Italo (ORCID:0000-0002-9854-5046)
Abstract: Background: The optimal access route in patients with severe peripheral artery disease (PAD) undergoing transcatheter aortic valve replacement (TAVR) remains undetermined. Objectives: This study sought to compare clinical outcomes with transfemoral access (TFA), transthoracic access (TTA), and nonthoracic transalternative access (TAA) in TAVR patients with severe PAD. Methods: Patients with PAD and hostile femoral access (TFA impossible, or possible only after percutaneous treatment) undergoing TAVR at 28 international centers were included in this registry. The primary endpoint was the propensity-adjusted risk of 30-day major adverse events (MAE) defined as the composite of all-cause mortality, stroke/transient ischemic attack (TIA), or main access site-related Valve Academic Research Consortium 3 major vascular complications. Outcomes were also stratified according to the severity of PAD using a novel risk score (Hostile score). Results: Among the 1,707 patients included in the registry, 518 (30.3%) underwent TAVR with TFA after percutaneous treatment, 642 (37.6%) with TTA, and 547 (32.0%) with TAA (mostly transaxillary). Compared with TTA, both TFA (adjusted HR: 0.58; 95% CI: 0.45-0.75) and TAA (adjusted HR: 0.60; 95% CI: 0.47-0.78) were associated with lower 30-day rates of MAE, driven by fewer access site-related complications. Composite risks at 1 year were also lower with TFA and TAA compared with TTA. TFA compared with TAA was associated with lower 1-year risk of stroke/TIA (adjusted HR: 0.49; 95% CI: 0.24-0.98), a finding confined to patients with low Hostile scores (Pinteraction = 0.049). Conclusions: Among patients with PAD undergoing TAVR, both TFA and TAA were associated with lower 30-day and 1-year rates of MAE compared with TTA, but 1-year stroke/TIA rates were higher with TAA compared with TFA.
Published: 2023

5. Clinical outcomes of the ACURATE neo2 transcatheter heart valve:a prospective, multicentre, observational, post-market surveillance study

Author: Kim, Won-Keun, Tamburino, Corrado, Möllmann, Helge, Montorfano, Matteo, Ellert-Gregersen, Julia, Rudolph, Tanja K., Van Mieghem, Nicolas M., Hilker, Michael, Amat-Santos, Ignacio J., Terkelsen, Christian Juhl, Petronio, Anna Sonia, Stella, Pieter R., Götberg, Matthias, Rück, Andreas, Kasel, A. Markus, Trillo, Ramiro, Appleby, Clare, Barbanti, Marco, Blanke, Philipp, Modolo, Rodrigo, Allocco, Dominic J., Sondergaard, Lars, Kim, Won-Keun, Tamburino, Corrado, Möllmann, Helge, Montorfano, Matteo, Ellert-Gregersen, Julia, Rudolph, Tanja K., Van Mieghem, Nicolas M., Hilker, Michael, Amat-Santos, Ignacio J., Terkelsen, Christian Juhl, Petronio, Anna Sonia, Stella, Pieter R., Götberg, Matthias, Rück, Andreas, Kasel, A. Markus, Trillo, Ramiro, Appleby, Clare, Barbanti, Marco, Blanke, Philipp, Modolo, Rodrigo, Allocco, Dominic J., and Sondergaard, Lars
Abstract: BACKGROUND: The next-generation ACURATE neo2 transcatheter aortic valve was designed for simplified implantation and to mitigate the risk of paravalvular leak (PVL) compared to the earlier device.AIMS: To collect clinical outcomes and device performance data, including echocardiography and 4-dimensional computed tomography (4D-CT) data, with the ACURATE neo2 transcatheter heart valve in patients with severe aortic stenosis (AS).METHODS: ACURATE neo2 PMCF is a single-arm, multicentre study of patients with severe AS treated in routine clinical practice. The primary safety endpoint was all-cause mortality at 30-days. The primary imaging endpoint was hypo-attenuated leaflet thickening (HALT), measured by core laboratory-adjudicated 4D-CT at 30 days. Secondary endpoints included VARC safety endpoints, procedural success, and evaluation of valve performance via core laboratory-adjudicated echocardiography.RESULTS: The study enrolled 250 patients at 18 European centres (mean age: 80.8 years; 63.6% female; mean STS score: 2.9±2.0%); 246 (98.4%) were successfully treated with ACURATE neo2. The 30-day rates for mortality and disabling stroke were 0.8% and 0%, respectively. The new permanent pacemaker implantation rate was 6.5%. HALT >50% was present in 9.3% of patients at 30 days. Valve haemodynamics improved from baseline to 30 days (mean aortic valve gradient: from 47.6±14.5 mmHg to 8.6±3.9 mmHg; mean aortic valve area: from 0.7±0.2 cm2 to 1.6±0.4 cm2). At 30 days, PVL was evaluated as none/trace in 79.2% of patients, mild in 18.9%, moderate in 1.9%, and severe in 0%.CONCLUSIONS: The study results support the safety and efficacy of TAVI with ACURATE neo2 in patients in routine clinical practice.
Published: 2023

6. Vascular Access in Patients With Peripheral Arterial Disease Undergoing TAVR:The Hostile Registry

Author: Palmerini, Tullio, Saia, Francesco, Kim, Won Keun, Renker, Matthias, Iadanza, Alessandro, Fineschi, Massimo, Bruno, Antonio Giulio, Ghetti, Gabriele, Vanhaverbeke, Maarten, Søndergaard, Lars, De Backer, Ole, Romagnoli, Enrico, Burzotta, Francesco, Trani, Carlo, Adrichem, Rik, Van Mieghem, Nicolas M., Nardi, Elena, Chietera, Francesco, Orzalkiewicz, Mateusz, Tomii, Daijiro, Pilgrim, Thomas, Aranzulla, Tiziana Claudia, Musumeci, Giuseppe, Adam, Matti, Meertens, Max M., Taglieri, Nevio, Marrozzini, Cinzia, Alvarez Covarrubias, Hector Alfonso, Joner, Michael, Nardi, Giulia, Di Muro, Francesca Maria, Di Mario, Carlo, Loretz, Lucca, Toggweiler, Stefan, Gallitto, Enrico, Gargiulo, Mauro, Testa, Luca, Bedogni, Francesco, Berti, Sergio, Ancona, Marco B., Montorfano, Matteo, Leone, Alessandro, Savini, Carlo, Pacini, Davide, Gmeiner, Jonas, Braun, Daniel, Nerla, Roberto, Castriota, Fausto, De Carlo, Marco, Petronio, Anna Sonia, Barbanti, Marco, Costa, Giuliano, Tamburino, Corrado, Leone, Pier Pasquale, Reimers, Bernhard, Stefanini, Giulio, Sudo, Mitsumasa, Nickenig, Georg, Piva, Tommaso, Scotti, Andrea, Latib, Azeem, Vercellino, Matteo, Porto, Italo, Codner, Pablo, Kornowski, Ran, Bartorelli, Antonio L., Tarantini, Giuseppe, Fraccaro, Chiara, Abdel-Wahab, Mohamed, Grube, Eberhard, Galié, Nazzareno, Stone, Gregg W., Palmerini, Tullio, Saia, Francesco, Kim, Won Keun, Renker, Matthias, Iadanza, Alessandro, Fineschi, Massimo, Bruno, Antonio Giulio, Ghetti, Gabriele, Vanhaverbeke, Maarten, Søndergaard, Lars, De Backer, Ole, Romagnoli, Enrico, Burzotta, Francesco, Trani, Carlo, Adrichem, Rik, Van Mieghem, Nicolas M., Nardi, Elena, Chietera, Francesco, Orzalkiewicz, Mateusz, Tomii, Daijiro, Pilgrim, Thomas, Aranzulla, Tiziana Claudia, Musumeci, Giuseppe, Adam, Matti, Meertens, Max M., Taglieri, Nevio, Marrozzini, Cinzia, Alvarez Covarrubias, Hector Alfonso, Joner, Michael, Nardi, Giulia, Di Muro, Francesca Maria, Di Mario, Carlo, Loretz, Lucca, Toggweiler, Stefan, Gallitto, Enrico, Gargiulo, Mauro, Testa, Luca, Bedogni, Francesco, Berti, Sergio, Ancona, Marco B., Montorfano, Matteo, Leone, Alessandro, Savini, Carlo, Pacini, Davide, Gmeiner, Jonas, Braun, Daniel, Nerla, Roberto, Castriota, Fausto, De Carlo, Marco, Petronio, Anna Sonia, Barbanti, Marco, Costa, Giuliano, Tamburino, Corrado, Leone, Pier Pasquale, Reimers, Bernhard, Stefanini, Giulio, Sudo, Mitsumasa, Nickenig, Georg, Piva, Tommaso, Scotti, Andrea, Latib, Azeem, Vercellino, Matteo, Porto, Italo, Codner, Pablo, Kornowski, Ran, Bartorelli, Antonio L., Tarantini, Giuseppe, Fraccaro, Chiara, Abdel-Wahab, Mohamed, Grube, Eberhard, Galié, Nazzareno, and Stone, Gregg W.
Abstract: Background: The optimal access route in patients with severe peripheral artery disease (PAD) undergoing transcatheter aortic valve replacement (TAVR) remains undetermined. Objectives: This study sought to compare clinical outcomes with transfemoral access (TFA), transthoracic access (TTA), and nonthoracic transalternative access (TAA) in TAVR patients with severe PAD. Methods: Patients with PAD and hostile femoral access (TFA impossible, or possible only after percutaneous treatment) undergoing TAVR at 28 international centers were included in this registry. The primary endpoint was the propensity-adjusted risk of 30-day major adverse events (MAE) defined as the composite of all-cause mortality, stroke/transient ischemic attack (TIA), or main access site–related Valve Academic Research Consortium 3 major vascular complications. Outcomes were also stratified according to the severity of PAD using a novel risk score (Hostile score). Results: Among the 1,707 patients included in the registry, 518 (30.3%) underwent TAVR with TFA after percutaneous treatment, 642 (37.6%) with TTA, and 547 (32.0%) with TAA (mostly transaxillary). Compared with TTA, both TFA (adjusted HR: 0.58; 95% CI: 0.45-0.75) and TAA (adjusted HR: 0.60; 95% CI: 0.47-0.78) were associated with lower 30-day rates of MAE, driven by fewer access site–related complications. Composite risks at 1 year were also lower with TFA and TAA compared with TTA. TFA compared with TAA was associated with lower 1-year risk of stroke/TIA (adjusted HR: 0.49; 95% CI: 0.24-0.98), a finding confined to patients with low Hostile scores (Pinteraction = 0.049). Conclusions: Among patients with PAD undergoing TAVR, both TFA and TAA were associated with lower 30-day and 1-year rates of MAE compared with TTA, but 1-year stroke/TIA rates were higher with TAA compared with TFA.
Published: 2023

7. Overcoming professional barriers encountered by women in interventional cardiology:an EAPCI statement

Author: Buchanan, Gill Louise, Paradies, Valeria, Karam, Nicole, Holmvang, Lene, Mamas, Mamas A., Mehilli, Julinda, Capodanno, Davide, Capranzano, Piera, Appelman, Yolande, Manzo-Silberman, Stéphane, Kunadian, Vijay, Mauri, Josepa, Shuepke, Stefanie, Petronio, Anna Sonia, Kaluzna-Oleksy, Marta, Gilard, Martine, Morice, Marie Claude, Barbato, Emanuele, Dudek, Dariusz, Chieffo, Alaide, Buchanan, Gill Louise, Paradies, Valeria, Karam, Nicole, Holmvang, Lene, Mamas, Mamas A., Mehilli, Julinda, Capodanno, Davide, Capranzano, Piera, Appelman, Yolande, Manzo-Silberman, Stéphane, Kunadian, Vijay, Mauri, Josepa, Shuepke, Stefanie, Petronio, Anna Sonia, Kaluzna-Oleksy, Marta, Gilard, Martine, Morice, Marie Claude, Barbato, Emanuele, Dudek, Dariusz, and Chieffo, Alaide
Abstract: Despite the increasing proportion of female medical and nursing students, there is still a significant under-representation of women working as healthcare providers in interventional cardiology, with very few of them reaching senior leadership, academic positions, or acting principal investigators, as well as actively involved in company advisory boards. In this position paper, we will describe the current status of women working in interventional cardiology across Europe. We will also provide an overview of the most relevant determinants of the under-representation of women at each stage of the interventional cardiology career path and offer practical suggestions for overcoming these challenges., Despite the increasing proportion of female medical and nursing students, there is still a significant under-representation of women working as healthcare providers in interventional cardiology, with very few of them reaching senior leadership, academic positions, or acting principal investigators, as well as actively involved in company advisory boards. In this position paper, we will describe the current status of women working in interventional cardiology across Europe. We will also provide an overview of the most relevant determinants of the under-representation of women at each stage of the interventional cardiology career path and offer practical suggestions for overcoming these challenges.
Published: 2023

8. Transcatheter Mitral Valve Replacement Versus Medical Therapy for Secondary Mitral Regurgitation:A Propensity Score-Matched Comparison

Author: Ludwig, Sebastian, Conradi, Lenard, Cohen, David J., Coisne, Augustin, Scotti, Andrea, Abraham, William T., Ben Ali, Walid, Zhou, Zhipeng, Li, Yanru, Kar, Saibal, Duncan, Alison, Scott Lim, D., Adamo, Marianna, Redfors, Björn, Muller, David W.M., Webb, John G., Petronio, Anna S., Ruge, Hendrik, Nickenig, Georg, Sondergaard, Lars, Adam, Matti, Regazzoli, Damiano, Garatti, Andrea, Schmidt, Tobias, Andreas, Martin, Dahle, Gry, Walther, Thomas, Kempfert, Joerg, Tang, Gilbert H.L., Redwood, Simon, Taramasso, Maurizio, Praz, Fabien, Fam, Neil, Dumonteil, Nicolas, Obadia, Jean François, Von Bardeleben, Ralph Stephan, Rudolph, Tanja K., Reardon, Michael J., Metra, Marco, Denti, Paolo, Mack, Michael J., Hausleiter, Jörg, Asch, Federico M., Latib, Azeem, Lindenfeld, Joann, Modine, Thomas, Stone, Gregg W., Granada, Juan F., Ludwig, Sebastian, Conradi, Lenard, Cohen, David J., Coisne, Augustin, Scotti, Andrea, Abraham, William T., Ben Ali, Walid, Zhou, Zhipeng, Li, Yanru, Kar, Saibal, Duncan, Alison, Scott Lim, D., Adamo, Marianna, Redfors, Björn, Muller, David W.M., Webb, John G., Petronio, Anna S., Ruge, Hendrik, Nickenig, Georg, Sondergaard, Lars, Adam, Matti, Regazzoli, Damiano, Garatti, Andrea, Schmidt, Tobias, Andreas, Martin, Dahle, Gry, Walther, Thomas, Kempfert, Joerg, Tang, Gilbert H.L., Redwood, Simon, Taramasso, Maurizio, Praz, Fabien, Fam, Neil, Dumonteil, Nicolas, Obadia, Jean François, Von Bardeleben, Ralph Stephan, Rudolph, Tanja K., Reardon, Michael J., Metra, Marco, Denti, Paolo, Mack, Michael J., Hausleiter, Jörg, Asch, Federico M., Latib, Azeem, Lindenfeld, Joann, Modine, Thomas, Stone, Gregg W., and Granada, Juan F.
Abstract: Background: Transcatheter mitral valve replacement (TMVR) is an emerging therapeutic alternative for patients with secondary mitral regurgitation (MR). Outcomes of TMVR versus guideline-directed medical therapy (GDMT) have not been investigated for this population. This study aimed to compare clinical outcomes of patients with secondary MR undergoing TMVR versus GDMT alone. Methods: The CHOICE-MI registry (Choice of Optimal Transcatheter Treatment for Mitral Insufficiency) included patients with MR undergoing TMVR using dedicated devices. Patients with MR pathogeneses other than secondary MR were excluded. Patients treated with GDMT alone were derived from the control arm of the COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation). We compared outcomes between the TMVR and GDMT groups, using propensity score matching to adjust for baseline differences. Results: After propensity score matching, 97 patient pairs undergoing TMVR (72.9±8.7 years; 60.8% men; transapical access, 91.8%) versus GDMT (73.1±11.0 years; 59.8% men) were compared. At 1 and 2 years, residual MR was ≤1+ in all patients of the TMVR group compared with 6.9% and 7.7%, respectively, in those receiving GDMT alone (both P<0.001). The 2-year rate of heart failure hospitalization was significantly lower in the TMVR group (32.8% versus 54.4%; hazard ratio, 0.59 [95% CI, 0.35–0.99]; P=0.04). Among survivors, a higher proportion of patients were in the New York Heart Association functional class I or II in the TMVR group at 1 year (78.2% versus 59.7%; P=0.03) and at 2 years (77.8% versus 53.2%; P=0.09). Two-year mortality was similar in the 2 groups (TMVR versus GDMT, 36.8% versus 40.8%; hazard ratio, 1.01 [95% CI, 0.62–1.64]; P=0.98). Conclusions: In this observational comparison, over 2-year follow-up, TMVR using mostly transapical devices in patients with secondar, Background: Transcatheter mitral valve replacement (TMVR) is an emerging therapeutic alternative for patients with secondary mitral regurgitation (MR). Outcomes of TMVR versus guideline-directed medical therapy (GDMT) have not been investigated for this population. This study aimed to compare clinical outcomes of patients with secondary MR undergoing TMVR versus GDMT alone. Methods: The CHOICE-MI registry (Choice of Optimal Transcatheter Treatment for Mitral Insufficiency) included patients with MR undergoing TMVR using dedicated devices. Patients with MR pathogeneses other than secondary MR were excluded. Patients treated with GDMT alone were derived from the control arm of the COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation). We compared outcomes between the TMVR and GDMT groups, using propensity score matching to adjust for baseline differences. Results: After propensity score matching, 97 patient pairs undergoing TMVR (72.9±8.7 years; 60.8% men; transapical access, 91.8%) versus GDMT (73.1±11.0 years; 59.8% men) were compared. At 1 and 2 years, residual MR was ≤1+ in all patients of the TMVR group compared with 6.9% and 7.7%, respectively, in those receiving GDMT alone (both P<0.001). The 2-year rate of heart failure hospitalization was significantly lower in the TMVR group (32.8% versus 54.4%; hazard ratio, 0.59 [95% CI, 0.35-0.99]; P=0.04). Among survivors, a higher proportion of patients were in the New York Heart Association functional class I or II in the TMVR group at 1 year (78.2% versus 59.7%; P=0.03) and at 2 years (77.8% versus 53.2%; P=0.09). Two-year mortality was similar in the 2 groups (TMVR versus GDMT, 36.8% versus 40.8%; hazard ratio, 1.01 [95% CI, 0.62-1.64]; P=0.98). Conclusions: In this observational comparison, over 2-year follow-up, TMVR using mostly transapical devices in patients with secondary MR was associated with significant red
Published: 2023

9. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis The Task Force for the management of COVID-19 of the European Society of Cardiology

Author: Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Hector, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-Philippe, Cuisset, Thomas, de Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, Gonzalez-Juanatey, Jose R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros, V, Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodriguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Luccia, Touyz, Rhian M., Wilde, Arthur A., Williams, Bryan, Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Hector, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-Philippe, Cuisset, Thomas, de Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, Gonzalez-Juanatey, Jose R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros, V, Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodriguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Luccia, Touyz, Rhian M., Wilde, Arthur A., and Williams, Bryan
Abstract: Aims Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two-part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular disease (CVD) in association with COVID-19. Methods and results A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, reported here, focuses on the epidemiology, pathophysiology, and diagnosis of cardiovascular (CV) conditions that may be manifest in patients with COVID-19. The second part, which will follow in a later edition of the journal, addresses the topics of care pathways, treatment, and follow-up of CV conditions in patients with COVID-19. Conclusion This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities. [GRAPHICS] .
Published: 2022

10. Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real-world multicentre experience

Author: Wild, Mirjam G., Kreidel, Felix, Hell, Michaela M., Praz, Fabien, Mach, Markus, Adam, Matti, Reineke, David, Ruge, Hendrik, Ludwig, Sebastian, Conradi, Lenard, Rudolph, Tanja K., Bleiziffer, Sabine, Kellermair, Joerg, Zierer, Andreas, Nickenig, Georg, Weber, Marcel, Petronio, Anna Sonia, Giannini, Cristina, Dahle, Gry, Rein, Kjell A., Coisne, Augustin, Vincentelli, Andre, Dubois, Christophe, Duncan, Alison, Quarto, Cesare, Unbehaun, Axel, Amat-Santos, Ignacio, Cobiella, Javier, Dumonteil, Nicolas, Estevez-Loureiro, Rodrigo, Fumero, Andrea, Geisler, Tobias, Lurz, Philipp, Mangieri, Antonio, Monivas, Vanessa, Noack, Thilo, Franco, Luis Nombela, Pinon, Miguel A., Stolz, Lukas, Tchetche, Didier, Walter, Thomas, Unsoeld, Bernhard, Baldus, Stephan, Andreas, Martin, Hausleiter, Joerg, von Bardeleben, Ralph S., Wild, Mirjam G., Kreidel, Felix, Hell, Michaela M., Praz, Fabien, Mach, Markus, Adam, Matti, Reineke, David, Ruge, Hendrik, Ludwig, Sebastian, Conradi, Lenard, Rudolph, Tanja K., Bleiziffer, Sabine, Kellermair, Joerg, Zierer, Andreas, Nickenig, Georg, Weber, Marcel, Petronio, Anna Sonia, Giannini, Cristina, Dahle, Gry, Rein, Kjell A., Coisne, Augustin, Vincentelli, Andre, Dubois, Christophe, Duncan, Alison, Quarto, Cesare, Unbehaun, Axel, Amat-Santos, Ignacio, Cobiella, Javier, Dumonteil, Nicolas, Estevez-Loureiro, Rodrigo, Fumero, Andrea, Geisler, Tobias, Lurz, Philipp, Mangieri, Antonio, Monivas, Vanessa, Noack, Thilo, Franco, Luis Nombela, Pinon, Miguel A., Stolz, Lukas, Tchetche, Didier, Walter, Thomas, Unsoeld, Bernhard, Baldus, Stephan, Andreas, Martin, Hausleiter, Joerg, and von Bardeleben, Ralph S.
Abstract: Aims Transcatheter mitral valve implantation (TMVI) is a new treatment option for patients with symptomatic mitral valve (MV) disease. Real-world data have not yet been reported. This study aimed to assess procedural and 30-day outcomes of TMVI in a real-world patient cohort. Method and results All consecutive patients undergoing implantation of a transapically delivered self-expanding valve at 26 European centres from January 2020 to April 2021 were included in this retrospective observational registry. Among 108 surgical high-risk patients included (43% female, mean age 75 +/- 7 years, mean STS-PROM 7.2 +/- 5.3%), 25% was treated for an off-label indication (e.g. previous MV intervention or surgery, mitral stenosis, mitral annular calcification). Patients were highly symptomatic (New York Heart Association [NYHA] functional class III/IV in 86%) and mitral regurgitation (MR) was graded 3+/4+ in 95% (38% primary, 37% secondary, and 25% mixed aetiology). Technical success rate was 96%, and MR reduction to <= 1+ was achieved in all patients with successful implantation. There were two procedural deaths and 30-day all-cause mortality was 12%. At early clinical follow-up, MR reduction was sustained and there were significant reductions of pulmonary pressure (systolic pulmonary artery pressure 52 vs. 42 mmHg, p < 0.001), and tricuspid regurgitation severity (p = 0.013). Heart failure symptoms improved significantly (73% in NYHA class I/II, p < 0.001). Procedural success rate according to MVARC criteria was 80% and was not different in patients treated for an off-label indication (74% vs. 81% for off- vs. on-label, p = 0.41). Conclusion In a real-world patient population, TMVI has a high technical and procedural success rate with efficient and durable MR reduction and symptomatic improvement.
Published: 2022

11. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

Author: Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Hector, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-Philippe, Cuisset, Thomas, de Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, Gonzalez-Juanatey, Jose R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros, V, Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodriguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Luccia, Touyz, Rhian M., Wilde, Arthur A., Williams, Bryan, Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Hector, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-Philippe, Cuisset, Thomas, de Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, Gonzalez-Juanatey, Jose R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros, V, Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodriguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Luccia, Touyz, Rhian M., Wilde, Arthur A., and Williams, Bryan
Abstract: Aims Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular (CV) disease in association with COVID-19. Methods and results A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, which was reported previously, focused on the epidemiology, pathophysiology, and diagnosis of CV conditions that may be manifest in patients with COVID-19. This second part addresses the topics of: care pathways and triage systems and management and treatment pathways, both of the most commonly encountered CV conditions and of COVID-19; and information that may be considered useful to help patients with CV disease (CVD) to avoid exposure to COVID-19. Conclusion This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities.
Published: 2022

12. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

Author: Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Hector, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-Philippe, Cuisset, Thomas, de Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, Gonzalez-Juanatey, Jose R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros, V, Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodriguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Luccia, Touyz, Rhian M., Wilde, Arthur A., Williams, Bryan, Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Hector, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-Philippe, Cuisset, Thomas, de Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, Gonzalez-Juanatey, Jose R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros, V, Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodriguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Luccia, Touyz, Rhian M., Wilde, Arthur A., and Williams, Bryan
Abstract: Aims Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two-part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular disease (CVD) in association with COVID-19. Methods and results A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, reported here, focuses on the epidemiology, pathophysiology, and diagnosis of cardiovascular (CV) conditions that may be manifest in patients with COVID-19. The second part, which will follow in a later edition of the journal, addresses the topics of care pathways, treatment, and follow-up of CV conditions in patients with COVID-19. Conclusion This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities.
Published: 2022

13. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

Author: Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Hector, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-Philippe, Cuisset, Thomas, de Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, Gonzalez-Juanatey, Jose R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros, V, Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodriguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Lucia, Touyz, Rhian M., Wilde, Arthur A., Williams, Bryan, Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Hector, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-Philippe, Cuisset, Thomas, de Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, Gonzalez-Juanatey, Jose R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros, V, Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodriguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Lucia, Touyz, Rhian M., Wilde, Arthur A., and Williams, Bryan
Abstract: Aims Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular (CV) disease in association with COVID-19. Methods and results A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, which was reported previously, focused on the epidemiology, pathophysiology, and diagnosis of CV conditions that may be manifest in patients with COVID-19. This second part addresses the topics of: care pathways and triage systems and management and treatment pathways, both of the most commonly encountered CV conditions and of COVID-19; and information that may be considered useful to help patients with CV disease (CVD) to avoid exposure to COVID-19. Conclusion This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities. [GRAPHICS] .
Published: 2022

14. Guideline-directed medical therapy in patients undergoing transcatheter edge-to-edge repair for secondary mitral regurgitation

Author: Higuchi, Satoshi, Orban, Mathias, Adamo, Marianna, Giannini, Cristina, Melica, Bruno, Karam, Nicole, Praz, Fabien, Kalbacher, Daniel, Koell, Benedikt, Stolz, Lukas, Braun, Daniel, Naebauer, Michael, Wild, Mirjam, Doldi, Philipp, Neuss, Michael, Butter, Christian, Kassar, Mohammad, Ruf, Tobias, Petrescu, Aniela, Ludwig, Sebastian, Pfister, Roman, Iliadis, Christos, Unterhuber, Matthias, Sampaio, Francisco, Ferreira, Diogo, Thiele, Holger, Baldus, Stephan, von Bardeleben, Ralph Stephan, Massberg, Steffen, Windecker, Stephan, Lurz, Philipp, Petronio, Anna Sonia, Lindenfeld, JoAnn, Abraham, William T., Metra, Marco, Hausleiter, Joeg, Higuchi, Satoshi, Orban, Mathias, Adamo, Marianna, Giannini, Cristina, Melica, Bruno, Karam, Nicole, Praz, Fabien, Kalbacher, Daniel, Koell, Benedikt, Stolz, Lukas, Braun, Daniel, Naebauer, Michael, Wild, Mirjam, Doldi, Philipp, Neuss, Michael, Butter, Christian, Kassar, Mohammad, Ruf, Tobias, Petrescu, Aniela, Ludwig, Sebastian, Pfister, Roman, Iliadis, Christos, Unterhuber, Matthias, Sampaio, Francisco, Ferreira, Diogo, Thiele, Holger, Baldus, Stephan, von Bardeleben, Ralph Stephan, Massberg, Steffen, Windecker, Stephan, Lurz, Philipp, Petronio, Anna Sonia, Lindenfeld, JoAnn, Abraham, William T., Metra, Marco, and Hausleiter, Joeg
Abstract: Aims Guideline-directed medical therapy (GDMT), based on the combination of beta-blockers (BB), renin-angiotensin system inhibitors (RASI), and mineralocorticoid receptor antagonists (MRA), is known to have a major impact on the outcome of patients with heart failure with reduced ejection fraction (HFrEF). Although GDMT is recommended prior to mitral valve transcatheter edge-to-edge repair (M-TEER), not all patients tolerate it. We studied the association of GDMT prescription with survival in HFrEF patients undergoing M-TEER for secondary mitral regurgitation (SMR). Methods and results EuroSMR, a European multicentre registry, included SMR patients with left ventricular ejection fraction <50%. The outcome was 2-year all-cause mortality. Of 1344 patients, BB, RASI, and MRA were prescribed in 1169 (87%), 1012 (75%), and 765 (57%) patients at the time of M-TEER, respectively. Triple GDMT prescription was associated with a lower 2-year all-cause mortality compared to non-triple GDMT (hazard ratio [HR] 0.74; 95% confidence interval [CI] 0.60-0.91). The association persisted in patients with glomerular filtration rate <30 ml/min, ischaemic aetiology, or right ventricular dysfunction. Further, a positive impact of triple GDMT prescription on survival was observed in patients with residual mitral regurgitation of >= 2+ (HR 0.62; 95% CI 0.44-0.86), but not in patients with residual mitral regurgitation of <= 1+ (HR 0.83; 95% CI 0.64-1.08). Conclusion Triple GDMT prescription is associated with higher 2-year survival after M-TEER in HFrEF patients with SMR. This association was consistent also in patients with major comorbidities or non-optimal results after M-TEER. [GRAPHICS] .
Published: 2022

15. Transcatheter Mitral Valve Repair in Patients With Atrial Functional Mitral Regurgitation

Author: Doldi, Philipp, Stolz, Lukas, Orban, Mathias, Karam, Nicole, Praz, Fabien, Kalbacher, Daniel, Lubos, Edith, Braun, Daniel, Adamo, Marianna, Giannini, Cristina, Melica, Bruno, Naebauer, Michael, Higuchi, Satoshi, Wild, Mirjam, Neuss, Michael, Butter, Christian, Kassar, Mohammad, Petrescu, Aniela, Pfister, Roman, Iliadis, Christos, Unterhuber, Matthias, Thiele, Holger, Baldus, Stephan, von Bardeleben, Ralph Stephan, Schofer, Niklas, Hagl, Christian, Petronio, Anna Sonia, Massberg, Steffen, Windecker, Stephan, Lurz, Philipp, Metra, Marco, Hausleiter, Joerg, Doldi, Philipp, Stolz, Lukas, Orban, Mathias, Karam, Nicole, Praz, Fabien, Kalbacher, Daniel, Lubos, Edith, Braun, Daniel, Adamo, Marianna, Giannini, Cristina, Melica, Bruno, Naebauer, Michael, Higuchi, Satoshi, Wild, Mirjam, Neuss, Michael, Butter, Christian, Kassar, Mohammad, Petrescu, Aniela, Pfister, Roman, Iliadis, Christos, Unterhuber, Matthias, Thiele, Holger, Baldus, Stephan, von Bardeleben, Ralph Stephan, Schofer, Niklas, Hagl, Christian, Petronio, Anna Sonia, Massberg, Steffen, Windecker, Stephan, Lurz, Philipp, Metra, Marco, and Hausleiter, Joerg
Abstract: BACKGROUND Among patients with severe functional mitral regurgitation (FMR), atrial functional mitral regurgitation (aFMR) represents an underrecognized entity. Data regarding outcomes after mitral valve transcatheter edge-to-edge repair (M-TEER) in aFMR remain scarce. OBJECTIVES The objective of this study was to analyze the outcome of aFMR patients undergoing M-TEER. METHODS Using patients from the international EuroSMR (European Registry of Transcatheter Repair for Secondary Mitral Regurgitation) registry undergoing M-TEER for FMR, the authors analyzed baseline characteristics and 2-year outcomes in aFMR in comparison to non-aFMR and ventricular FMR. Additionally, the impact of right ventricular dysfunction (RVD) (defined as right ventricular to pulmonary artery uncoupling) on outcome after M-TEER was assessed. RESULTS Among 1,608 FMR patients treated by M-TEER, 126 (7.8%) were categorized as aFMR. All 126 aFMR patients had preserved left ventricular function without regional wall motion abnormalities, left arterial dilatation and Carpentier leaflet motion type I. Procedural success (defined as mitral regurgitation #2thorn at discharge) was 87.2% (P < 0.001) and New York Heart Association (NYHA) functional class significantly improved during follow-up (NYHA functional class III/IV: 86.5% at baseline to 36.6% at follow-up; P< 0.001). The estimated 2-year survival rate in aFMR patients was 70.4%. Twoyear survival did not differ significantly between aFMR, non-aFMR, and ventricular FMR. Besides NYHA functional class IV, RVD was identified as a strong independent predictor for 2-year survival (HR: 2.82 [95% CI: 1.24-6.45]; P = 0.014). CONCLUSIONS aFMR is a frequent cause of FMR and can be effectively treated with M-TEER to improve symptoms at follow-up. Advanced heart failure symptoms and RVD were identified as important risk factors for survival in aFMR patients. (J Am Coll Cardiol Img 2022;15:1843-1851) (c) 2022 by the American College of Cardiology Foundation.
Published: 2022

16. Left atrial volume index and outcome after transcatheter edge-to-edge valve repair for secondary mitral regurgitation

Author: Iliadis, Christos, Kalbacher, Daniel, Lurz, Philipp, Petrescu, Aniela Monica, Orban, Mathias, Puscas, Tania, Lupi, Laura, Stazzoni, Laura, Pires-Morais, Gustavo, Koell, Benedikt, Besler, Christian, Ruf, Tobias Friedrich, Stolz, Lukas, Tence, Noemie, Adamo, Marianna, Giannini, Cristina, Guerreiro, Claudio, Hellmich, Martin, Baldus, Stephan, Schofer, Niklas, Thiele, Holger, von Bardeleben, Ralph Stephan, Hausleiter, Joerg, Karam, Nicole, Metra, Marco, Petronio, Anna Sonia, Melica, Bruno, Pfister, Roman, Iliadis, Christos, Kalbacher, Daniel, Lurz, Philipp, Petrescu, Aniela Monica, Orban, Mathias, Puscas, Tania, Lupi, Laura, Stazzoni, Laura, Pires-Morais, Gustavo, Koell, Benedikt, Besler, Christian, Ruf, Tobias Friedrich, Stolz, Lukas, Tence, Noemie, Adamo, Marianna, Giannini, Cristina, Guerreiro, Claudio, Hellmich, Martin, Baldus, Stephan, Schofer, Niklas, Thiele, Holger, von Bardeleben, Ralph Stephan, Hausleiter, Joerg, Karam, Nicole, Metra, Marco, Petronio, Anna Sonia, Melica, Bruno, and Pfister, Roman
Abstract: Aims To investigate the role of left atrial volume index (LAVi) in patients with secondary mitral regurgitation (SMR) undergoing transcatheter edge-to-edge mitral valve repair (TEER). Methods and results Outcomes were evaluated in SMR patients of a European multicentre registry according to baseline LAVi. Main analysis was performed for all-cause mortality; residual mitral regurgitation (MR) and New York Heart Association (NYHA) class improvement were analysed for patients available. A total of 1074 patients were included with a median LAVi (interquartile range) of 58 ml/m(2) (46-73). Postprocedural reduction of MR grade to <= 2+ was similar across LAVi quintiles, ranging 91%-96% (p = 0.26). Symptomatic benefit (>= 1 NYHA class improvement) also did not differ by LAVi quintiles (61%-68% of patients) (p = 0.66). The risk of mortality increased by 23%-42% in the four upper quintiles compared to the bottom quintile (LAVi <42 ml/m(2)). The hazard ratio (HR) of mortality was 1.35 (95% confidence interval [CI] 1.02-1.78, p = 0.035) associated with a LAVi >42 ml/m(2), which was attenuated after multivariable adjustment (HR 1.18, 95% CI 0.83-1.67, p = 0.36). A significant interaction was found for MR severity and pulmonary hypertension, with an increased risk of death associated with enlarged LAVi in patients with inframedian effective regurgitant orifice area (HR 1.99, 95% CI 1.06-3.74, p = 0.032) and in patients with systolic pulmonary pressure <= 50 mmHg (HR 1.67, 95% CI 1.02-2.75, p = 0.042) in multivariable analysis. Conclusion Procedural success and symptomatic benefit were high throughout the whole range of LAVi. The prognostic impact of left atrial enlargement was relevant in patients with less severe SMR and without pulmonary hypertension, reinforcing the need to identify patients in the early course of backward congestion to achieve good long-term outcome after TEER.
Published: 2022

17. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic:part 2-care pathways, treatment, and follow-up

Author: Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L, Baumbach, Andreas, Behr, Elijah R, Berti, Sergio, Bueno, Héctor, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-Philippe, Cuisset, Thomas, de Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, González-Juanatey, José R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J, Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A, Konstantinides, Stavros V., Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M, Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L, Baumbach, Andreas, Behr, Elijah R, Berti, Sergio, Bueno, Héctor, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-Philippe, Cuisset, Thomas, de Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, González-Juanatey, José R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J, Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A, Konstantinides, Stavros V., Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M, Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, and Price, Susanna
Abstract: Aims: Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular (CV) disease in association with COVID-19. Methods and results: A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, which was reported previously, focused on the epidemiology, pathophysiology, and diagnosis of CV conditions that may be manifest in patients with COVID-19. This second part addresses the topics of: care pathways and triage systems and management and treatment pathways, both of the most commonly encountered CV conditions and of COVID-19; and information that may be considered useful to help patients with CV disease (CVD) to avoid exposure to COVID-19. Conclusion: This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities.
Published: 2022

18. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic:part 1 - epidemiology, pathophysiology, and diagnosis

Author: Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Héctor, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean Philippe, Cuisset, Thomas, De Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, González-Juanatey, José R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros V., Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodríguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Lucia, Touyz, Rhian M., Wilde, Arthur A., Williams, Bryan, Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Héctor, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean Philippe, Cuisset, Thomas, De Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, González-Juanatey, José R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros V., Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodríguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Lucia, Touyz, Rhian M., Wilde, Arthur A., and Williams, Bryan
Abstract: Aims: Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two-part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular disease (CVD) in association with COVID-19. Methods and results: A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, reported here, focuses on the epidemiology, pathophysiology, and diagnosis of cardiovascular (CV) conditions that may be manifest in patients with COVID-19. The second part, which will follow in a later edition of the journal, addresses the topics of care pathways, treatment, and follow-up of CV conditions in patients with COVID-19. Conclusion: This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities.
Published: 2022

19. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up

Author: Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L, Baumbach, Andreas, Behr, Elijah R, Berti, Sergio, Bueno, Héctor, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-philippe, Cuisset, Thomas, De Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, González-juanatey, José R, Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J, Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A, Konstantinides, Stavros V, Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M, Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodríguez-leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R, Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Luccia, Touyz, Rhian M, Wilde, Arthur A, Williams, Bryan, Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L, Baumbach, Andreas, Behr, Elijah R, Berti, Sergio, Bueno, Héctor, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean-philippe, Cuisset, Thomas, De Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, González-juanatey, José R, Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J, Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A, Konstantinides, Stavros V, Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M, Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodríguez-leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R, Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Luccia, Touyz, Rhian M, Wilde, Arthur A, and Williams, Bryan
Abstract: Aims Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular (CV) disease in association with COVID-19. Methods and results A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, which was reported previously, focused on the epidemiology, pathophysiology, and diagnosis of CV conditions that may be manifest in patients with COVID-19. This second part addresses the topics of: care pathways and triage systems and management and treatment pathways, both of the most commonly encountered CV conditions and of COVID-19; and information that may be considered useful to help patients with CV disease (CVD) to avoid exposure to COVID-19. Conclusion This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities.
Published: 2022

20. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic:part 1 - epidemiology, pathophysiology, and diagnosis

Author: Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Héctor, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean Philippe, Cuisset, Thomas, De Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, González-Juanatey, José R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros V., Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodríguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Lucia, Touyz, Rhian M., Wilde, Arthur A., Williams, Bryan, Baigent, Colin, Windecker, Stephan, Andreini, Daniele, Arbelo, Elena, Barbato, Emanuele, Bartorelli, Antonio L., Baumbach, Andreas, Behr, Elijah R., Berti, Sergio, Bueno, Héctor, Capodanno, Davide, Cappato, Riccardo, Chieffo, Alaide, Collet, Jean Philippe, Cuisset, Thomas, De Simone, Giovanni, Delgado, Victoria, Dendale, Paul, Dudek, Dariusz, Edvardsen, Thor, Elvan, Arif, González-Juanatey, José R., Gori, Mauro, Grobbee, Diederick, Guzik, Tomasz J., Halvorsen, Sigrun, Haude, Michael, Heidbuchel, Hein, Hindricks, Gerhard, Ibanez, Borja, Karam, Nicole, Katus, Hugo, Klok, Fredrikus A., Konstantinides, Stavros V., Landmesser, Ulf, Leclercq, Christophe, Leonardi, Sergio, Lettino, Maddalena, Marenzi, Giancarlo, Mauri, Josepa, Metra, Marco, Morici, Nuccia, Mueller, Christian, Petronio, Anna Sonia, Polovina, Marija M., Potpara, Tatjana, Praz, Fabien, Prendergast, Bernard, Prescott, Eva, Price, Susanna, Pruszczyk, Piotr, Rodríguez-Leor, Oriol, Roffi, Marco, Romaguera, Rafael, Rosenkranz, Stephan, Sarkozy, Andrea, Scherrenberg, Martijn, Seferovic, Petar, Senni, Michele, Spera, Francesco R., Stefanini, Giulio, Thiele, Holger, Tomasoni, Daniela, Torracca, Lucia, Touyz, Rhian M., Wilde, Arthur A., and Williams, Bryan
Abstract: Aims: Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two-part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular disease (CVD) in association with COVID-19. Methods and results: A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, reported here, focuses on the epidemiology, pathophysiology, and diagnosis of cardiovascular (CV) conditions that may be manifest in patients with COVID-19. The second part, which will follow in a later edition of the journal, addresses the topics of care pathways, treatment, and follow-up of CV conditions in patients with COVID-19. Conclusion: This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities.
Published: 2022

21. Predictors of early discharge after transcatheter aortic valve implantation: insight from the CoreValve ClinicalService

Author: Angelillis, Marco, Costa, Giulia, Giannini, Cristina, Fiorina, Claudia, Branca, Luca, Tamburino, Corrado, Barbanti, Marco, Gorla, Riccardo, Casenghi, Matteo, Bruschi, Giuseppe, Merlanti, Bruno, Montorfano, Matteo, Ferri, Luca A, Poli, Arnaldo, Regazzoli, Damiano, De Felice, Francesco, Maffeo, Diego, Trani, Carlo, Iadanza, Alessandro, Petronio, Anna S, Trani, Carlo (ORCID:0000-0001-9777-013X), Angelillis, Marco, Costa, Giulia, Giannini, Cristina, Fiorina, Claudia, Branca, Luca, Tamburino, Corrado, Barbanti, Marco, Gorla, Riccardo, Casenghi, Matteo, Bruschi, Giuseppe, Merlanti, Bruno, Montorfano, Matteo, Ferri, Luca A, Poli, Arnaldo, Regazzoli, Damiano, De Felice, Francesco, Maffeo, Diego, Trani, Carlo, Iadanza, Alessandro, Petronio, Anna S, and Trani, Carlo (ORCID:0000-0001-9777-013X)
Abstract: N/A
Published: 2022

22. Transcatheter Mitral Valve Replacement After Surgical Repair or Replacement Comprehensive Midterm Evaluation of Valve-in-Valve and Valve-in-Ring Implantation From the VIVID Registry

Author: Simonato, Matheus, Whisenant, Brian, Ribeiro, Henrique Barbosa, Webb, John G., Kornowski, Ran, Guerrero, Mayra, Wijeysundera, Harindra, Sondergaard, Lars, De Backer, Ole, Villablanca, Pedro, Rihal, Charanjit, Eleid, Mackram, Kempfert, Jorg, Unbehaun, Axel, Erlebach, Magdalena, Casselman, Filip, Adam, Matti, Montorfano, Matteo, Ancona, Marco, Saia, Francesco, Ubben, Timm, Meincke, Felix, Napodano, Massimo, Codner, Pablo, Schofer, Joachim, Pelletier, Marc, Cheung, Anson, Shuvy, Mony, Palma, Jose Honorio, Gaia, Diego Felipe, Duncan, Alison, Hildick-Smith, David, Veulemans, Verena, Sinning, Jan-Malte, Arbel, Yaron, Testa, Luca, de Weger, Arend, Eltchaninoff, Helene, Hemery, Thibault, Landes, Uri, Tchetche, Didier, Dumonteil, Nicolas, Rodes-Cabau, Josep, Kim, Won-Keun, Spargias, Konstantinos, Kourkoveli, Panagiota, Ben-Yehuda, Ori, Teles, Rui Campante, Barbanti, Marco, Fiorina, Claudia, Thukkani, Arun, Mackensen, G. Burkhard, Jones, Noah, Presbitero, Patrizia, Petronio, Anna Sonia, Allali, Abdelhakim, Champagnac, Didier, Bleiziffer, Sabine, Rudolph, Tanja, Iadanza, Alessandro, Salizzoni, Stefano, Agrifoglio, Marco, Nombela-Franco, Luis, Bonaros, Nikolaos, Kass, Malek, Bruschi, Giuseppe, Amabile, Nicolas, Chhatriwalla, Adnan, Messina, Antonio, Hirji, Sameer A., Andreas, Martin, Welsh, Robert, Schoels, Wolfgang, Hellig, Farrel, Windecker, Stephan, Stortecky, Stefan, Maisano, Francesco, Stone, Gregg W., Dvir, Danny, Simonato, Matheus, Whisenant, Brian, Ribeiro, Henrique Barbosa, Webb, John G., Kornowski, Ran, Guerrero, Mayra, Wijeysundera, Harindra, Sondergaard, Lars, De Backer, Ole, Villablanca, Pedro, Rihal, Charanjit, Eleid, Mackram, Kempfert, Jorg, Unbehaun, Axel, Erlebach, Magdalena, Casselman, Filip, Adam, Matti, Montorfano, Matteo, Ancona, Marco, Saia, Francesco, Ubben, Timm, Meincke, Felix, Napodano, Massimo, Codner, Pablo, Schofer, Joachim, Pelletier, Marc, Cheung, Anson, Shuvy, Mony, Palma, Jose Honorio, Gaia, Diego Felipe, Duncan, Alison, Hildick-Smith, David, Veulemans, Verena, Sinning, Jan-Malte, Arbel, Yaron, Testa, Luca, de Weger, Arend, Eltchaninoff, Helene, Hemery, Thibault, Landes, Uri, Tchetche, Didier, Dumonteil, Nicolas, Rodes-Cabau, Josep, Kim, Won-Keun, Spargias, Konstantinos, Kourkoveli, Panagiota, Ben-Yehuda, Ori, Teles, Rui Campante, Barbanti, Marco, Fiorina, Claudia, Thukkani, Arun, Mackensen, G. Burkhard, Jones, Noah, Presbitero, Patrizia, Petronio, Anna Sonia, Allali, Abdelhakim, Champagnac, Didier, Bleiziffer, Sabine, Rudolph, Tanja, Iadanza, Alessandro, Salizzoni, Stefano, Agrifoglio, Marco, Nombela-Franco, Luis, Bonaros, Nikolaos, Kass, Malek, Bruschi, Giuseppe, Amabile, Nicolas, Chhatriwalla, Adnan, Messina, Antonio, Hirji, Sameer A., Andreas, Martin, Welsh, Robert, Schoels, Wolfgang, Hellig, Farrel, Windecker, Stephan, Stortecky, Stefan, Maisano, Francesco, Stone, Gregg W., and Dvir, Danny
Abstract: Background: Mitral valve-in-valve (ViV) and valve-in-ring (ViR) are alternatives to surgical reoperation in patients with recurrent mitral valve failure after previous surgical valve repair or replacement. Our aim was to perform a large-scale analysis examining midterm outcomes after mitral ViV and ViR. Methods: Patients undergoing mitral ViV and ViR were enrolled in the Valve-in-Valve International Data Registry. Cases were performed between March 2006 and March 2020. Clinical endpoints are reported according to the Mitral Valve Academic Research Consortium (MVARC) definitions. Significant residual mitral stenosis (MS) was defined as mean gradient >= 10 mm Hg and significant residual mitral regurgitation (MR) as >= moderate. Results: A total of 1079 patients (857 ViV, 222 ViR; mean age 73.5 +/- 12.5 years; 40.8% male) from 90 centers were included. Median STS-PROM score 8.6%; median clinical follow-up 492 days (interquartile range, 76-996); median echocardiographic follow-up for patients that survived 1 year was 772.5 days (interquartile range, 510-1211.75). Four-year Kaplan-Meier survival rate was 62.5% in ViV versus 49.5% for ViR (P<0.001). Mean gradient across the mitral valve postprocedure was 5.7 +/- 2.8 mm Hg (>= 5 mm Hg; 61.4% of patients). Significant residual MS occurred in 8.2% of the ViV and 12.0% of the ViR patients (P=0.09). Significant residual MR was more common in ViR patients (16.6% versus 3.1%; P<0.001) and was associated with lower survival at 4 years (35.1% versus 61.6%; P=0.02). The rates of Mitral Valve Academic Research Consortium-defined device success were low for both procedures (39.4% total; 32.0% ViR versus 41.3% ViV; P=0.01), mostly related to having postprocedural mean gradient >= 5 mm Hg. Correlates for residual MS were smaller true internal diameter, younger age, and larger body mass index. The only correlate for residual MR was ViR. Significant residual MS (subhazard ratio, 4.67; 95% CI, 1.74-12.56; P=0.002) and significant residual
Published: 2021

23. Outcomes Stratified by Adapted Inclusion Criteria After Mitral Edge-to-Edge Repair

Author: Koell, Benedikt, Orban, Mathias, Weimann, Jessica, Kassar, Mohammad, Karam, Nicole, Neuss, Michael, Petrescu, Aniela, Iliadis, Christos, Unterhuber, Matthias, Adamo, Marianna, Giannini, Cristina, Melica, Bruno, Ludwig, Sebastian, Massberg, Steffen, Praz, Fabien, Pfister, Roman, Thiele, Holger, von Bardeleben, Ralph Stephan, Baldus, Stephan, Butter, Christian, Lurz, Philipp, Windecker, Stephan, Metra, Marco, Petronio, Anna Sonia, Hausleiter, Joerg, Lubos, Edith, Kalbacher, Daniel, Koell, Benedikt, Orban, Mathias, Weimann, Jessica, Kassar, Mohammad, Karam, Nicole, Neuss, Michael, Petrescu, Aniela, Iliadis, Christos, Unterhuber, Matthias, Adamo, Marianna, Giannini, Cristina, Melica, Bruno, Ludwig, Sebastian, Massberg, Steffen, Praz, Fabien, Pfister, Roman, Thiele, Holger, von Bardeleben, Ralph Stephan, Baldus, Stephan, Butter, Christian, Lurz, Philipp, Windecker, Stephan, Metra, Marco, Petronio, Anna Sonia, Hausleiter, Joerg, Lubos, Edith, and Kalbacher, Daniel
Abstract: BACKGROUND Although mitral valve transcatheter edge-to-edge repair (M-TEER) achieves symptomatic benefit for a broad spectrum of patients with relevant secondary mitral regurgitation, conflicting data exist on its prognostic impact. OBJECTIVES Adapted enrollment criteria approaching those used in the COAPT (Cardiovascular Outcomes Assessment of the MitraCtip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) and MITRA-FR (Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation) trials were retrospectively applied to a European real-world registry to evaluate the influence of the respective criteria on outcomes. METHODS A total of 1,022 patients included in the EuroSMR (European Registry of Transcatheter Repair for Secondary Mitral Regurgitation) registry and treated with M-TEER (November 2008 to September 2019) were stratified into COAPT-eligible (n = 353 [34.5%)) and COAPT-ineligible (n = 669 [65.5%]) as well as MITRA-FR-eligible (n = 408 [48.3%]) and MITRA-FR-ineligible (n = 437 [51.7%]) groups. RESULTS Although the stratification of patients according to adapted MITRA-FR criteria led to comparable outcomes regarding all-cause mortality (P = 0.19), the application of adapted COAPT enrollment criteria demonstrated lower mortality rates in COAPT-eligible compared with COAPT-ineligible patients (P < 0.001). Multivariable Cox regression analysis identified New York Heart Association functional class IV (hazard ratio [HR]: 2.29; 95% confidence interval (Ca: 1.53-3.42; P < 0.001), logarithmic N-terminal pro-brain natriuretic peptide (HR: 1.47; 95% CI: 1.24-1.75; P < 0.001), and right ventricular-to-pulmonary arterial coupling (HR: 0.10; 95% 0: 0.02-0.57; P 0.009) as independent predictors of outcome. Yet improvement of functional outcome was demonstrated in a subset of patients irrespective of COAPT eligibility status. CONCLUSIONS In this real-world cohort of patients with secondary mitral regurgitation undergoing M
Published: 2021

24. Transcatheter Aortic Valve Replacement With the LOTUS Edge System Early European Experience

Author: Armario, Xavier, Rosseel, Liesbeth, Kharbanda, Rajesh, Khogali, Saib, Abdel-Wahab, Mohamed, Van Mieghem, Nicolas M., Tchetche, Didier, Dumonteil, Nicolas, De Backer, Ole, Cotton, James, McGrath, Brian, Balakrishnan, Deepu, Ali, Noman, Farhan, Serdar, Joseph, Jubin, Charbonnier, Gaetan, Okuno, Taishi, McHugh, Fiachra, Hildick-Smith, David, Gilgen, Nicole, Hokken, Thijmen, Spence, Mark S., Frerker, Christian, Angelillis, Marco, Grygier, Marek, Cockburn, James, Bjursten, Henrik, Jeger, Raban, V, Teles, Rui, Petronio, Anna S., Pilgrim, Thomas, Sinning, Jan-Malte, Nickenig, Georg, Sondergaard, Lars, Blackman, Daniel J., Mylotte, Darren, Armario, Xavier, Rosseel, Liesbeth, Kharbanda, Rajesh, Khogali, Saib, Abdel-Wahab, Mohamed, Van Mieghem, Nicolas M., Tchetche, Didier, Dumonteil, Nicolas, De Backer, Ole, Cotton, James, McGrath, Brian, Balakrishnan, Deepu, Ali, Noman, Farhan, Serdar, Joseph, Jubin, Charbonnier, Gaetan, Okuno, Taishi, McHugh, Fiachra, Hildick-Smith, David, Gilgen, Nicole, Hokken, Thijmen, Spence, Mark S., Frerker, Christian, Angelillis, Marco, Grygier, Marek, Cockburn, James, Bjursten, Henrik, Jeger, Raban, V, Teles, Rui, Petronio, Anna S., Pilgrim, Thomas, Sinning, Jan-Malte, Nickenig, Georg, Sondergaard, Lars, Blackman, Daniel J., and Mylotte, Darren
Abstract: OBJECTIVES The aim of this study was to evaluate the short-term safety and efficacy of transcatheter aortic valve replacement (TAVR) with the LOTUS Edge system. BACKGROUND The LOTUS Edge system was commercially re-released in April 2019. The authors report the first European experience with this device. METHODS A multicenter, single-arm, retrospective registry was initiated to evaluate short-term clinical outcomes. Included cases are the first experience with this device and new implantation technique in Europe. Clinical, echocardiographic, and computed tomographic data were analyzed. Endpoints were defined according to Valve Academic Research Consortium-2 and were site reported. RESULTS Between April and November 2019, 286 consecutive patients undergoing TAVR with the LOTUS Edge system at 18 European centers were included. The mean age and Society of Thoracic Surgeons score were 81.2 +/- 6.9 years and 5.2 +/- 5.4%, respectively. Nearly one-half of all patients (47.9%) were considered to have complex anatomy. Thirty-day major adverse events included death (2.4% [n = 7]) and stroke (3.5% [n = 10]). After TAVR, the mean aortic valve area was 1.9 +/- 0.9 cm(2), and the mean transvalvular gradient was 11.9 +/- 5.7 mm Hg. None or trace paravalvular leak (PVL) occurred in 84.4% and moderate PVL in 2.0%. There were no cases of severe PVL. New permanent pacemaker (PPM) implantation was required in 25.9% among all patients and 30.8% among PPM-naive patients. CONCLUSIONS Early experience with the LOTUS Edge system demonstrated satisfactory short-term safety and efficacy, favorable hemodynamic data, and very low rates of PVL in an anatomically complex cohort. New PPM implantation remained high. Further study will evaluate if increasing operator experience with the device and new implantation technique can reduce the incidence of PPM implantation. (c) 2021 by the American College of Cardiology Foundation.
Published: 2021

25. Permanent Pacemaker Implantation Following Valve-in-Valve Transcatheter Aortic Valve Replacement

Author: Alperi, Alberto, Rodes-Cabau, Josep, Simonato, Matheus, Tchetche, Didier, Charbonnier, Gaetan, Ribeiro, Henrique B., Latib, Azeem, Montorfano, Matteo, Barbanti, Marco, Bleiziffer, Sabine, Redfors, Bjorn, Abdel-Wahab, Mohamed, Allali, Abdelhakim, Bruschi, Giuseppe, Napodano, Massimo, Agrifoglio, Marco, Petronio, Anna Sonia, Giannini, Cristina, Chan, Albert, Kornowski, Ran, Pravda, Nili Schamroth, Adam, Matti, Iadanza, Alessandro, Noble, Stephane, Chatfield, Andrew, Erlebach, Magdalena, Kempfert, Joerg, Ubben, Timm, Wijeysundera, Harindra, Seiffert, Moritz, Pilgrim, Thomas, Kim, Won-Keun, Testa, Luca, Hildick-Smith, David, Nerla, Roberto, Fiorina, Claudia, Brinkmann, Christina, Conzelmann, Lars, Champagnac, Didier, Saia, Francesco, Nissen, Henrik, Amrane, Hafid, Whisenant, Brian, Shamekhi, Jasmin, Sondergaard, Lars, Webb, John G., Dvir, Danny, Alperi, Alberto, Rodes-Cabau, Josep, Simonato, Matheus, Tchetche, Didier, Charbonnier, Gaetan, Ribeiro, Henrique B., Latib, Azeem, Montorfano, Matteo, Barbanti, Marco, Bleiziffer, Sabine, Redfors, Bjorn, Abdel-Wahab, Mohamed, Allali, Abdelhakim, Bruschi, Giuseppe, Napodano, Massimo, Agrifoglio, Marco, Petronio, Anna Sonia, Giannini, Cristina, Chan, Albert, Kornowski, Ran, Pravda, Nili Schamroth, Adam, Matti, Iadanza, Alessandro, Noble, Stephane, Chatfield, Andrew, Erlebach, Magdalena, Kempfert, Joerg, Ubben, Timm, Wijeysundera, Harindra, Seiffert, Moritz, Pilgrim, Thomas, Kim, Won-Keun, Testa, Luca, Hildick-Smith, David, Nerla, Roberto, Fiorina, Claudia, Brinkmann, Christina, Conzelmann, Lars, Champagnac, Didier, Saia, Francesco, Nissen, Henrik, Amrane, Hafid, Whisenant, Brian, Shamekhi, Jasmin, Sondergaard, Lars, Webb, John G., and Dvir, Danny
Abstract: BACKGROUND Permanent pacemaker implantation (PPI) remains one of the main drawbacks of transcatheter aortic valve replacement (TAVR), but scarce data exist on PPI after valve-in-valve (ViV) TAVR, particularly with the use of newer-generation transcatheter heart valves (THVs). OBJECTIVES The goal of this study was to determine the incidence, factors associated with, and clinical impact of PPI in a large series of ViV-TAVR procedures. METHODS Data were obtained from the multicenter VIVID Registry and included the main baseline and procedural characteristics, in-hospital and late (median follow-up: 13 months [interquartile range: 3 to 41 months]) outcomes analyzed according to the need of periprocedural PPI. All THVs except CoreValve, Cribier-Edwards, Sapien, and Sapien XT were considered to be new-generation THVs. RESULTS A total of 1,987 patients without prior PPI undergoing ViV-TAVR from 2007 to 2020 were included. Of these, 128 patients (6.4%) had PPI after TAVR, with a significant decrease in the incidence of PPI with the use of new-generation THVs (4.7% vs. 7.4%; p = 0.017), mainly related to a reduced PPI rate with the Evolut R/Pro versus CoreValve (3.7% vs. 9.0%; p = 0.002). There were no significant differences in PPI rates between newer-generation balloon-and self expanding THVs (6.1% vs. 3.9%; p = 0.18). In the multivariable analysis, older age (odds ratio [OR]: 1.05 for each increase of 1 year; 95% confidence interval [CI]: 1.02 to 1.07; p = 0.001), larger THV size (OR: 1.10; 95% CI: 1.01 to 1.20; p = 0.02), and previous right bundle branch block (OR: 2.04; 95% CI: 1.00 to 4.17; p = 0.05) were associated with an increased risk of PPI. There were no differences in 30-day mortality between the PPI (4.7%) and no-PPI (2.7%) groups (p = 0.19), but PPI patients exhibited a trend toward higher mortality risk at follow-up (hazard ratio: 1.39; 95% CI: 1.02 to 1.91; p = 0.04; p = 0.08 after adjusting for age differences between groups). CONCLUSIONS In a contemporary
Published: 2021

26. EAPCI Core Curriculum for Percutaneous Cardiovascular Interventions (2020): Committee for Education and Training European Association of Percutaneous Cardiovascular Interventions (EAPCI). A branch of the European Society of Cardiology.

Author: UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, Van Belle, Eric, Teles, Rui C, Pyxaras, Stylianos A, Kalpak, Oliver, Johnson, Thomas William, Barbash, Israel Moshe, De Luca, Giuseppe, Kostov, Jorgo, Parma, Radoslaw, Vincent, Flavien, Brugaletta, Salvatore, Debry, Nicolas, Toth, Gabor G, Ghazzal, Ziyad, Deharo, Pierre, Milasinovic, Dejan, Kaspar, Klaus, Saia, Francesco, Mauri Ferre, Josepa, Kammler, Jürgen, Muir, Douglas F, O'Connor, Stephen, Mehilli, Julinda, Thiele, Holger, Weilenmann, Daniel, Witt, Nils, Joshi, Francis, Kharbanda, Rajesh K, Piroth, Zsolt, Wojakowski, Wojciech, Geppert, Alexander, Di Gioia, Giuseppe, Pires-Morais, Gustavo, Petronio, Anna Sonia, Estevez-Loureiro, Rodrigo, Ruzsa, Zoltán, Kefer, Joëlle, Kunadian, Vijay, Van Mieghem, Nicolas, Windecker, Stephan, Baumbach, Andreas, Haude, Michael, Dudek, Dariusz, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, Van Belle, Eric, Teles, Rui C, Pyxaras, Stylianos A, Kalpak, Oliver, Johnson, Thomas William, Barbash, Israel Moshe, De Luca, Giuseppe, Kostov, Jorgo, Parma, Radoslaw, Vincent, Flavien, Brugaletta, Salvatore, Debry, Nicolas, Toth, Gabor G, Ghazzal, Ziyad, Deharo, Pierre, Milasinovic, Dejan, Kaspar, Klaus, Saia, Francesco, Mauri Ferre, Josepa, Kammler, Jürgen, Muir, Douglas F, O'Connor, Stephen, Mehilli, Julinda, Thiele, Holger, Weilenmann, Daniel, Witt, Nils, Joshi, Francis, Kharbanda, Rajesh K, Piroth, Zsolt, Wojakowski, Wojciech, Geppert, Alexander, Di Gioia, Giuseppe, Pires-Morais, Gustavo, Petronio, Anna Sonia, Estevez-Loureiro, Rodrigo, Ruzsa, Zoltán, Kefer, Joëlle, Kunadian, Vijay, Van Mieghem, Nicolas, Windecker, Stephan, Baumbach, Andreas, Haude, Michael, and Dudek, Dariusz
Abstract: The proposed 2020 Core Curriculum for Percutaneous Cardiovascular Interventions aims to provide an updated European consensus that defines the level of experience and knowledge in the field of percutaneous cardiovascular intervention (PCI). It promotes homogenous education and training programmes among countries, and is the cornerstone of the new EAPCI certification, designed to support the recognition of competencies at the European level and the free movement of certified specialists in the European Community. It is based on a thorough review of the ESC guidelines and of the EAPCI textbook on percutaneous interventional cardiovascular medicine. The structure of the current core curriculum evolved from previous EAPCI core curricula and from the "2013 core curriculum of the general cardiologist" to follow the current ESC recommendations for core curricula. In most subject areas, there was a wide - if not unanimous - consensus among the task force members on the training required for the interventional cardiologist of the future. The document recommends that acquisition of competence in interventional cardiology requires at least two years of postgraduate training, in addition to four years devoted to cardiology. The first part of the curriculum covers general aspects of training and is followed by a comprehensive description of the specific components in 54 chapters. Each of the chapters includes statements of the objectives, and is further subdivided into the required knowledge, skills, behaviours, and attitudes.
Published: 2021

27. Transcatheter mitral valve replacement after surgical repair or replacement:comprehensive midterm evaluation of valve-in-valve and valve-in-ring implantation from the VIVID registry

Author: Simonato, Matheus, Whisenant, Brian, Ribeiro, Henrique Barbosa, Webb, John G., Kornowski, Ran, Guerrero, Mayra, Wijeysundera, Harindra, Søndergaard, Lars, de Backer, Ole, Villablanca, Pedro, Rihal, Charanjit, Eleid, Mackram, Kempfert, Jörg, Unbehaun, Axel, Erlebach, Magdalena, Casselman, Filip, Adam, Matti, Montorfano, Matteo, Ancona, Marco, Saia, Francesco, Ubben, Timm, Meincke, Felix, Napodano, Massimo, Codner, Pablo, Schofer, Joachim, Pelletier, Marc, Cheung, Anson, Shuvy, Mony, Palma, José Honório, Gaia, Diego Felipe, Duncan, Alison, Hildick-Smith, David, Veulemans, Verena, Sinning, Jan Malte, Arbel, Yaron, Testa, Luca, de Weger, Arend, Eltchaninoff, Helene, Hemery, Thibault, Landes, Uri, Tchetche, Didier, Dumonteil, Nicolas, Rodés-Cabau, Josep, Kim, Won Keun, Spargias, Konstantinos, Kourkoveli, Panagiota, Ben-Yehuda, Ori, Teles, Rui Campante, Barbanti, Marco, Fiorina, Claudia, Thukkani, Arun, Mackensen, G. Burkhard, Jones, Noah, Presbitero, Patrizia, Petronio, Anna Sonia, Allali, Abdelhakim, Champagnac, Didier, Bleiziffer, Sabine, Rudolph, Tanja, Iadanza, Alessandro, Salizzoni, Stefano, Agrifoglio, Marco, Nombela-Franco, Luis, Bonaros, Nikolaos, Kass, Malek, Bruschi, Giuseppe, Amabile, Nicolas, Chhatriwalla, Adnan, Messina, Antonio, Hirji, Sameer A., Andreas, Martin, Welsh, Robert, Schoels, Wolfgang, Hellig, Farrel, Windecker, Stephan, Stortecky, Stefan, Maisano, Francesco, Stone, Gregg W., Dvir, Danny, Simonato, Matheus, Whisenant, Brian, Ribeiro, Henrique Barbosa, Webb, John G., Kornowski, Ran, Guerrero, Mayra, Wijeysundera, Harindra, Søndergaard, Lars, de Backer, Ole, Villablanca, Pedro, Rihal, Charanjit, Eleid, Mackram, Kempfert, Jörg, Unbehaun, Axel, Erlebach, Magdalena, Casselman, Filip, Adam, Matti, Montorfano, Matteo, Ancona, Marco, Saia, Francesco, Ubben, Timm, Meincke, Felix, Napodano, Massimo, Codner, Pablo, Schofer, Joachim, Pelletier, Marc, Cheung, Anson, Shuvy, Mony, Palma, José Honório, Gaia, Diego Felipe, Duncan, Alison, Hildick-Smith, David, Veulemans, Verena, Sinning, Jan Malte, Arbel, Yaron, Testa, Luca, de Weger, Arend, Eltchaninoff, Helene, Hemery, Thibault, Landes, Uri, Tchetche, Didier, Dumonteil, Nicolas, Rodés-Cabau, Josep, Kim, Won Keun, Spargias, Konstantinos, Kourkoveli, Panagiota, Ben-Yehuda, Ori, Teles, Rui Campante, Barbanti, Marco, Fiorina, Claudia, Thukkani, Arun, Mackensen, G. Burkhard, Jones, Noah, Presbitero, Patrizia, Petronio, Anna Sonia, Allali, Abdelhakim, Champagnac, Didier, Bleiziffer, Sabine, Rudolph, Tanja, Iadanza, Alessandro, Salizzoni, Stefano, Agrifoglio, Marco, Nombela-Franco, Luis, Bonaros, Nikolaos, Kass, Malek, Bruschi, Giuseppe, Amabile, Nicolas, Chhatriwalla, Adnan, Messina, Antonio, Hirji, Sameer A., Andreas, Martin, Welsh, Robert, Schoels, Wolfgang, Hellig, Farrel, Windecker, Stephan, Stortecky, Stefan, Maisano, Francesco, Stone, Gregg W., and Dvir, Danny
Abstract: BACKGROUND: Mitral valve-in-valve (ViV) and valve-in-ring (ViR) are alternatives to surgical reoperation in patients with recurrent mitral valve failure after previous surgical valve repair or replacement. Our aim was to perform a large-scale analysis examining midterm outcomes after mitral ViV and ViR. METHODS: Patients undergoing mitral ViV and ViR were enrolled in the Valve-in-Valve International Data Registry. Cases were performed between March 2006 and March 2020. Clinical endpoints are reported according to the Mitral Valve Academic Research Consortium (MVARC) definitions. Significant residual mitral stenosis (MS) was defined as mean gradient ≥10 mmHg and significant residual mitral regurgitation (MR) as ≥ moderate. RESULTS: A total of 1079 patients (857 ViV, 222 ViR; mean age 73.5±12.5 years; 40.8% male) from 90 centers were included. Median STS-PROM score 8.6%; median clinical follow-up 492 days (interquartile range, 76-996); median echocardiographic follow-up for patients that survived 1 year was 772.5 days (interquartile range, 510-1211.75). Four-year Kaplan-Meier survival rate was 62.5% in ViV versus 49.5% for ViR (P<0.001). Mean gradient across the mitral valve postprocedure was 5.7±2.8 mmHg (≥5 mmHg; 61.4% of patients). Significant residual MS occurred in 8.2% of the ViV and 12.0% of the ViR patients (P=0.09). Significant residual MR was more common in ViR patients (16.6% versus 3.1%; P<0.001) and was associated with lower survival at 4 years (35.1% versus 61.6%; P=0.02). The rates of Mitral Valve Academic Research Consortium-defined device success were low for both procedures (39.4% total; 32.0% ViR versus 41.3% ViV; P=0.01), mostly related to having postprocedural mean gradient ≥5 mmHg. Correlates for residual MS were smaller true internal diameter, younger age, and larger body mass index. The only correlate for residual MR was ViR. Significant residual MS (subhazard ratio, 4.67; 95% CI, 1.74-12.56; P=0.002) and significant residual MR (subha
Published: 2021

28. Permanent Pacemaker Implantation Following Valve-in-Valve Transcatheter Aortic Valve Replacement

Author: Alperi, Alberto, Rodes-Cabau, Josep, Simonato, Matheus, Tchetche, Didier, Charbonnier, Gaetan, Ribeiro, Henrique B., Latib, Azeem, Montorfano, Matteo, Barbanti, Marco, Bleiziffer, Sabine, Redfors, Bjorn, Abdel-Wahab, Mohamed, Allali, Abdelhakim, Bruschi, Giuseppe, Napodano, Massimo, Agrifoglio, Marco, Petronio, Anna Sonia, Giannini, Cristina, Chan, Albert, Kornowski, Ran, Pravda, Nili Schamroth, Adam, Matti, Iadanza, Alessandro, Noble, Stephane, Chatfield, Andrew, Erlebach, Magdalena, Kempfert, Joerg, Ubben, Timm, Wijeysundera, Harindra, Seiffert, Moritz, Pilgrim, Thomas, Kim, Won-Keun, Testa, Luca, Hildick-Smith, David, Nerla, Roberto, Fiorina, Claudia, Brinkmann, Christina, Conzelmann, Lars, Champagnac, Didier, Saia, Francesco, Nissen, Henrik, Amrane, Hafid, Whisenant, Brian, Shamekhi, Jasmin, Sondergaard, Lars, Webb, John G., Dvir, Danny, Alperi, Alberto, Rodes-Cabau, Josep, Simonato, Matheus, Tchetche, Didier, Charbonnier, Gaetan, Ribeiro, Henrique B., Latib, Azeem, Montorfano, Matteo, Barbanti, Marco, Bleiziffer, Sabine, Redfors, Bjorn, Abdel-Wahab, Mohamed, Allali, Abdelhakim, Bruschi, Giuseppe, Napodano, Massimo, Agrifoglio, Marco, Petronio, Anna Sonia, Giannini, Cristina, Chan, Albert, Kornowski, Ran, Pravda, Nili Schamroth, Adam, Matti, Iadanza, Alessandro, Noble, Stephane, Chatfield, Andrew, Erlebach, Magdalena, Kempfert, Joerg, Ubben, Timm, Wijeysundera, Harindra, Seiffert, Moritz, Pilgrim, Thomas, Kim, Won-Keun, Testa, Luca, Hildick-Smith, David, Nerla, Roberto, Fiorina, Claudia, Brinkmann, Christina, Conzelmann, Lars, Champagnac, Didier, Saia, Francesco, Nissen, Henrik, Amrane, Hafid, Whisenant, Brian, Shamekhi, Jasmin, Sondergaard, Lars, Webb, John G., and Dvir, Danny
Abstract: BACKGROUND Permanent pacemaker implantation (PPI) remains one of the main drawbacks of transcatheter aortic valve replacement (TAVR), but scarce data exist on PPI after valve-in-valve (ViV) TAVR, particularly with the use of newer-generation transcatheter heart valves (THVs). OBJECTIVES The goal of this study was to determine the incidence, factors associated with, and clinical impact of PPI in a large series of ViV-TAVR procedures. METHODS Data were obtained from the multicenter VIVID Registry and included the main baseline and procedural characteristics, in-hospital and late (median follow-up: 13 months [interquartile range: 3 to 41 months]) outcomes analyzed according to the need of periprocedural PPI. All THVs except CoreValve, Cribier-Edwards, Sapien, and Sapien XT were considered to be new-generation THVs. RESULTS A total of 1,987 patients without prior PPI undergoing ViV-TAVR from 2007 to 2020 were included. Of these, 128 patients (6.4%) had PPI after TAVR, with a significant decrease in the incidence of PPI with the use of new-generation THVs (4.7% vs. 7.4%; p = 0.017), mainly related to a reduced PPI rate with the Evolut R/Pro versus CoreValve (3.7% vs. 9.0%; p = 0.002). There were no significant differences in PPI rates between newer-generation balloon-and self expanding THVs (6.1% vs. 3.9%; p = 0.18). In the multivariable analysis, older age (odds ratio [OR]: 1.05 for each increase of 1 year; 95% confidence interval [CI]: 1.02 to 1.07; p = 0.001), larger THV size (OR: 1.10; 95% CI: 1.01 to 1.20; p = 0.02), and previous right bundle branch block (OR: 2.04; 95% CI: 1.00 to 4.17; p = 0.05) were associated with an increased risk of PPI. There were no differences in 30-day mortality between the PPI (4.7%) and no-PPI (2.7%) groups (p = 0.19), but PPI patients exhibited a trend toward higher mortality risk at follow-up (hazard ratio: 1.39; 95% CI: 1.02 to 1.91; p = 0.04; p = 0.08 after adjusting for age differences between groups). CONCLUSIONS In a contemporary
Published: 2021

29. Transcatheter Mitral Valve Replacement After Surgical Repair or Replacement Comprehensive Midterm Evaluation of Valve-in-Valve and Valve-in-Ring Implantation From the VIVID Registry

Author: Simonato, Matheus, Whisenant, Brian, Ribeiro, Henrique Barbosa, Webb, John G., Kornowski, Ran, Guerrero, Mayra, Wijeysundera, Harindra, Sondergaard, Lars, De Backer, Ole, Villablanca, Pedro, Rihal, Charanjit, Eleid, Mackram, Kempfert, Jorg, Unbehaun, Axel, Erlebach, Magdalena, Casselman, Filip, Adam, Matti, Montorfano, Matteo, Ancona, Marco, Saia, Francesco, Ubben, Timm, Meincke, Felix, Napodano, Massimo, Codner, Pablo, Schofer, Joachim, Pelletier, Marc, Cheung, Anson, Shuvy, Mony, Palma, Jose Honorio, Gaia, Diego Felipe, Duncan, Alison, Hildick-Smith, David, Veulemans, Verena, Sinning, Jan-Malte, Arbel, Yaron, Testa, Luca, de Weger, Arend, Eltchaninoff, Helene, Hemery, Thibault, Landes, Uri, Tchetche, Didier, Dumonteil, Nicolas, Rodes-Cabau, Josep, Kim, Won-Keun, Spargias, Konstantinos, Kourkoveli, Panagiota, Ben-Yehuda, Ori, Teles, Rui Campante, Barbanti, Marco, Fiorina, Claudia, Thukkani, Arun, Mackensen, G. Burkhard, Jones, Noah, Presbitero, Patrizia, Petronio, Anna Sonia, Allali, Abdelhakim, Champagnac, Didier, Bleiziffer, Sabine, Rudolph, Tanja, Iadanza, Alessandro, Salizzoni, Stefano, Agrifoglio, Marco, Nombela-Franco, Luis, Bonaros, Nikolaos, Kass, Malek, Bruschi, Giuseppe, Amabile, Nicolas, Chhatriwalla, Adnan, Messina, Antonio, Hirji, Sameer A., Andreas, Martin, Welsh, Robert, Schoels, Wolfgang, Hellig, Farrel, Windecker, Stephan, Stortecky, Stefan, Maisano, Francesco, Stone, Gregg W., Dvir, Danny, Simonato, Matheus, Whisenant, Brian, Ribeiro, Henrique Barbosa, Webb, John G., Kornowski, Ran, Guerrero, Mayra, Wijeysundera, Harindra, Sondergaard, Lars, De Backer, Ole, Villablanca, Pedro, Rihal, Charanjit, Eleid, Mackram, Kempfert, Jorg, Unbehaun, Axel, Erlebach, Magdalena, Casselman, Filip, Adam, Matti, Montorfano, Matteo, Ancona, Marco, Saia, Francesco, Ubben, Timm, Meincke, Felix, Napodano, Massimo, Codner, Pablo, Schofer, Joachim, Pelletier, Marc, Cheung, Anson, Shuvy, Mony, Palma, Jose Honorio, Gaia, Diego Felipe, Duncan, Alison, Hildick-Smith, David, Veulemans, Verena, Sinning, Jan-Malte, Arbel, Yaron, Testa, Luca, de Weger, Arend, Eltchaninoff, Helene, Hemery, Thibault, Landes, Uri, Tchetche, Didier, Dumonteil, Nicolas, Rodes-Cabau, Josep, Kim, Won-Keun, Spargias, Konstantinos, Kourkoveli, Panagiota, Ben-Yehuda, Ori, Teles, Rui Campante, Barbanti, Marco, Fiorina, Claudia, Thukkani, Arun, Mackensen, G. Burkhard, Jones, Noah, Presbitero, Patrizia, Petronio, Anna Sonia, Allali, Abdelhakim, Champagnac, Didier, Bleiziffer, Sabine, Rudolph, Tanja, Iadanza, Alessandro, Salizzoni, Stefano, Agrifoglio, Marco, Nombela-Franco, Luis, Bonaros, Nikolaos, Kass, Malek, Bruschi, Giuseppe, Amabile, Nicolas, Chhatriwalla, Adnan, Messina, Antonio, Hirji, Sameer A., Andreas, Martin, Welsh, Robert, Schoels, Wolfgang, Hellig, Farrel, Windecker, Stephan, Stortecky, Stefan, Maisano, Francesco, Stone, Gregg W., and Dvir, Danny
Abstract: Background: Mitral valve-in-valve (ViV) and valve-in-ring (ViR) are alternatives to surgical reoperation in patients with recurrent mitral valve failure after previous surgical valve repair or replacement. Our aim was to perform a large-scale analysis examining midterm outcomes after mitral ViV and ViR. Methods: Patients undergoing mitral ViV and ViR were enrolled in the Valve-in-Valve International Data Registry. Cases were performed between March 2006 and March 2020. Clinical endpoints are reported according to the Mitral Valve Academic Research Consortium (MVARC) definitions. Significant residual mitral stenosis (MS) was defined as mean gradient >= 10 mm Hg and significant residual mitral regurgitation (MR) as >= moderate. Results: A total of 1079 patients (857 ViV, 222 ViR; mean age 73.5 +/- 12.5 years; 40.8% male) from 90 centers were included. Median STS-PROM score 8.6%; median clinical follow-up 492 days (interquartile range, 76-996); median echocardiographic follow-up for patients that survived 1 year was 772.5 days (interquartile range, 510-1211.75). Four-year Kaplan-Meier survival rate was 62.5% in ViV versus 49.5% for ViR (P<0.001). Mean gradient across the mitral valve postprocedure was 5.7 +/- 2.8 mm Hg (>= 5 mm Hg; 61.4% of patients). Significant residual MS occurred in 8.2% of the ViV and 12.0% of the ViR patients (P=0.09). Significant residual MR was more common in ViR patients (16.6% versus 3.1%; P<0.001) and was associated with lower survival at 4 years (35.1% versus 61.6%; P=0.02). The rates of Mitral Valve Academic Research Consortium-defined device success were low for both procedures (39.4% total; 32.0% ViR versus 41.3% ViV; P=0.01), mostly related to having postprocedural mean gradient >= 5 mm Hg. Correlates for residual MS were smaller true internal diameter, younger age, and larger body mass index. The only correlate for residual MR was ViR. Significant residual MS (subhazard ratio, 4.67; 95% CI, 1.74-12.56; P=0.002) and significant residual
Published: 2021

30. Transcatheter Aortic Valve Replacement With the LOTUS Edge System Early European Experience

Author: Armario, Xavier, Rosseel, Liesbeth, Kharbanda, Rajesh, Khogali, Saib, Abdel-Wahab, Mohamed, Van Mieghem, Nicolas M., Tchetche, Didier, Dumonteil, Nicolas, De Backer, Ole, Cotton, James, McGrath, Brian, Balakrishnan, Deepu, Ali, Noman, Farhan, Serdar, Joseph, Jubin, Charbonnier, Gaetan, Okuno, Taishi, McHugh, Fiachra, Hildick-Smith, David, Gilgen, Nicole, Hokken, Thijmen, Spence, Mark S., Frerker, Christian, Angelillis, Marco, Grygier, Marek, Cockburn, James, Bjursten, Henrik, Jeger, Raban, V, Teles, Rui, Petronio, Anna S., Pilgrim, Thomas, Sinning, Jan-Malte, Nickenig, Georg, Sondergaard, Lars, Blackman, Daniel J., Mylotte, Darren, Armario, Xavier, Rosseel, Liesbeth, Kharbanda, Rajesh, Khogali, Saib, Abdel-Wahab, Mohamed, Van Mieghem, Nicolas M., Tchetche, Didier, Dumonteil, Nicolas, De Backer, Ole, Cotton, James, McGrath, Brian, Balakrishnan, Deepu, Ali, Noman, Farhan, Serdar, Joseph, Jubin, Charbonnier, Gaetan, Okuno, Taishi, McHugh, Fiachra, Hildick-Smith, David, Gilgen, Nicole, Hokken, Thijmen, Spence, Mark S., Frerker, Christian, Angelillis, Marco, Grygier, Marek, Cockburn, James, Bjursten, Henrik, Jeger, Raban, V, Teles, Rui, Petronio, Anna S., Pilgrim, Thomas, Sinning, Jan-Malte, Nickenig, Georg, Sondergaard, Lars, Blackman, Daniel J., and Mylotte, Darren
Abstract: OBJECTIVES The aim of this study was to evaluate the short-term safety and efficacy of transcatheter aortic valve replacement (TAVR) with the LOTUS Edge system. BACKGROUND The LOTUS Edge system was commercially re-released in April 2019. The authors report the first European experience with this device. METHODS A multicenter, single-arm, retrospective registry was initiated to evaluate short-term clinical outcomes. Included cases are the first experience with this device and new implantation technique in Europe. Clinical, echocardiographic, and computed tomographic data were analyzed. Endpoints were defined according to Valve Academic Research Consortium-2 and were site reported. RESULTS Between April and November 2019, 286 consecutive patients undergoing TAVR with the LOTUS Edge system at 18 European centers were included. The mean age and Society of Thoracic Surgeons score were 81.2 +/- 6.9 years and 5.2 +/- 5.4%, respectively. Nearly one-half of all patients (47.9%) were considered to have complex anatomy. Thirty-day major adverse events included death (2.4% [n = 7]) and stroke (3.5% [n = 10]). After TAVR, the mean aortic valve area was 1.9 +/- 0.9 cm(2), and the mean transvalvular gradient was 11.9 +/- 5.7 mm Hg. None or trace paravalvular leak (PVL) occurred in 84.4% and moderate PVL in 2.0%. There were no cases of severe PVL. New permanent pacemaker (PPM) implantation was required in 25.9% among all patients and 30.8% among PPM-naive patients. CONCLUSIONS Early experience with the LOTUS Edge system demonstrated satisfactory short-term safety and efficacy, favorable hemodynamic data, and very low rates of PVL in an anatomically complex cohort. New PPM implantation remained high. Further study will evaluate if increasing operator experience with the device and new implantation technique can reduce the incidence of PPM implantation. (c) 2021 by the American College of Cardiology Foundation.
Published: 2021

31. Outcomes Stratified by Adapted Inclusion Criteria After Mitral Edge-to-Edge Repair

Author: Koell, Benedikt, Orban, Mathias, Weimann, Jessica, Kassar, Mohammad, Karam, Nicole, Neuss, Michael, Petrescu, Aniela, Iliadis, Christos, Unterhuber, Matthias, Adamo, Marianna, Giannini, Cristina, Melica, Bruno, Ludwig, Sebastian, Massberg, Steffen, Praz, Fabien, Pfister, Roman, Thiele, Holger, von Bardeleben, Ralph Stephan, Baldus, Stephan, Butter, Christian, Lurz, Philipp, Windecker, Stephan, Metra, Marco, Petronio, Anna Sonia, Hausleiter, Joerg, Lubos, Edith, Kalbacher, Daniel, Koell, Benedikt, Orban, Mathias, Weimann, Jessica, Kassar, Mohammad, Karam, Nicole, Neuss, Michael, Petrescu, Aniela, Iliadis, Christos, Unterhuber, Matthias, Adamo, Marianna, Giannini, Cristina, Melica, Bruno, Ludwig, Sebastian, Massberg, Steffen, Praz, Fabien, Pfister, Roman, Thiele, Holger, von Bardeleben, Ralph Stephan, Baldus, Stephan, Butter, Christian, Lurz, Philipp, Windecker, Stephan, Metra, Marco, Petronio, Anna Sonia, Hausleiter, Joerg, Lubos, Edith, and Kalbacher, Daniel
Abstract: BACKGROUND Although mitral valve transcatheter edge-to-edge repair (M-TEER) achieves symptomatic benefit for a broad spectrum of patients with relevant secondary mitral regurgitation, conflicting data exist on its prognostic impact. OBJECTIVES Adapted enrollment criteria approaching those used in the COAPT (Cardiovascular Outcomes Assessment of the MitraCtip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) and MITRA-FR (Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation) trials were retrospectively applied to a European real-world registry to evaluate the influence of the respective criteria on outcomes. METHODS A total of 1,022 patients included in the EuroSMR (European Registry of Transcatheter Repair for Secondary Mitral Regurgitation) registry and treated with M-TEER (November 2008 to September 2019) were stratified into COAPT-eligible (n = 353 [34.5%)) and COAPT-ineligible (n = 669 [65.5%]) as well as MITRA-FR-eligible (n = 408 [48.3%]) and MITRA-FR-ineligible (n = 437 [51.7%]) groups. RESULTS Although the stratification of patients according to adapted MITRA-FR criteria led to comparable outcomes regarding all-cause mortality (P = 0.19), the application of adapted COAPT enrollment criteria demonstrated lower mortality rates in COAPT-eligible compared with COAPT-ineligible patients (P < 0.001). Multivariable Cox regression analysis identified New York Heart Association functional class IV (hazard ratio [HR]: 2.29; 95% confidence interval (Ca: 1.53-3.42; P < 0.001), logarithmic N-terminal pro-brain natriuretic peptide (HR: 1.47; 95% CI: 1.24-1.75; P < 0.001), and right ventricular-to-pulmonary arterial coupling (HR: 0.10; 95% 0: 0.02-0.57; P 0.009) as independent predictors of outcome. Yet improvement of functional outcome was demonstrated in a subset of patients irrespective of COAPT eligibility status. CONCLUSIONS In this real-world cohort of patients with secondary mitral regurgitation undergoing M
Published: 2021

32. Transcatheter mitral valve replacement after surgical repair or replacement:comprehensive midterm evaluation of valve-in-valve and valve-in-ring implantation from the VIVID registry

Author: Simonato, Matheus, Whisenant, Brian, Ribeiro, Henrique Barbosa, Webb, John G., Kornowski, Ran, Guerrero, Mayra, Wijeysundera, Harindra, Søndergaard, Lars, de Backer, Ole, Villablanca, Pedro, Rihal, Charanjit, Eleid, Mackram, Kempfert, Jörg, Unbehaun, Axel, Erlebach, Magdalena, Casselman, Filip, Adam, Matti, Montorfano, Matteo, Ancona, Marco, Saia, Francesco, Ubben, Timm, Meincke, Felix, Napodano, Massimo, Codner, Pablo, Schofer, Joachim, Pelletier, Marc, Cheung, Anson, Shuvy, Mony, Palma, José Honório, Gaia, Diego Felipe, Duncan, Alison, Hildick-Smith, David, Veulemans, Verena, Sinning, Jan Malte, Arbel, Yaron, Testa, Luca, de Weger, Arend, Eltchaninoff, Helene, Hemery, Thibault, Landes, Uri, Tchetche, Didier, Dumonteil, Nicolas, Rodés-Cabau, Josep, Kim, Won Keun, Spargias, Konstantinos, Kourkoveli, Panagiota, Ben-Yehuda, Ori, Teles, Rui Campante, Barbanti, Marco, Fiorina, Claudia, Thukkani, Arun, Mackensen, G. Burkhard, Jones, Noah, Presbitero, Patrizia, Petronio, Anna Sonia, Allali, Abdelhakim, Champagnac, Didier, Bleiziffer, Sabine, Rudolph, Tanja, Iadanza, Alessandro, Salizzoni, Stefano, Agrifoglio, Marco, Nombela-Franco, Luis, Bonaros, Nikolaos, Kass, Malek, Bruschi, Giuseppe, Amabile, Nicolas, Chhatriwalla, Adnan, Messina, Antonio, Hirji, Sameer A., Andreas, Martin, Welsh, Robert, Schoels, Wolfgang, Hellig, Farrel, Windecker, Stephan, Stortecky, Stefan, Maisano, Francesco, Stone, Gregg W., Dvir, Danny, Simonato, Matheus, Whisenant, Brian, Ribeiro, Henrique Barbosa, Webb, John G., Kornowski, Ran, Guerrero, Mayra, Wijeysundera, Harindra, Søndergaard, Lars, de Backer, Ole, Villablanca, Pedro, Rihal, Charanjit, Eleid, Mackram, Kempfert, Jörg, Unbehaun, Axel, Erlebach, Magdalena, Casselman, Filip, Adam, Matti, Montorfano, Matteo, Ancona, Marco, Saia, Francesco, Ubben, Timm, Meincke, Felix, Napodano, Massimo, Codner, Pablo, Schofer, Joachim, Pelletier, Marc, Cheung, Anson, Shuvy, Mony, Palma, José Honório, Gaia, Diego Felipe, Duncan, Alison, Hildick-Smith, David, Veulemans, Verena, Sinning, Jan Malte, Arbel, Yaron, Testa, Luca, de Weger, Arend, Eltchaninoff, Helene, Hemery, Thibault, Landes, Uri, Tchetche, Didier, Dumonteil, Nicolas, Rodés-Cabau, Josep, Kim, Won Keun, Spargias, Konstantinos, Kourkoveli, Panagiota, Ben-Yehuda, Ori, Teles, Rui Campante, Barbanti, Marco, Fiorina, Claudia, Thukkani, Arun, Mackensen, G. Burkhard, Jones, Noah, Presbitero, Patrizia, Petronio, Anna Sonia, Allali, Abdelhakim, Champagnac, Didier, Bleiziffer, Sabine, Rudolph, Tanja, Iadanza, Alessandro, Salizzoni, Stefano, Agrifoglio, Marco, Nombela-Franco, Luis, Bonaros, Nikolaos, Kass, Malek, Bruschi, Giuseppe, Amabile, Nicolas, Chhatriwalla, Adnan, Messina, Antonio, Hirji, Sameer A., Andreas, Martin, Welsh, Robert, Schoels, Wolfgang, Hellig, Farrel, Windecker, Stephan, Stortecky, Stefan, Maisano, Francesco, Stone, Gregg W., and Dvir, Danny
Abstract: BACKGROUND: Mitral valve-in-valve (ViV) and valve-in-ring (ViR) are alternatives to surgical reoperation in patients with recurrent mitral valve failure after previous surgical valve repair or replacement. Our aim was to perform a large-scale analysis examining midterm outcomes after mitral ViV and ViR. METHODS: Patients undergoing mitral ViV and ViR were enrolled in the Valve-in-Valve International Data Registry. Cases were performed between March 2006 and March 2020. Clinical endpoints are reported according to the Mitral Valve Academic Research Consortium (MVARC) definitions. Significant residual mitral stenosis (MS) was defined as mean gradient ≥10 mmHg and significant residual mitral regurgitation (MR) as ≥ moderate. RESULTS: A total of 1079 patients (857 ViV, 222 ViR; mean age 73.5±12.5 years; 40.8% male) from 90 centers were included. Median STS-PROM score 8.6%; median clinical follow-up 492 days (interquartile range, 76-996); median echocardiographic follow-up for patients that survived 1 year was 772.5 days (interquartile range, 510-1211.75). Four-year Kaplan-Meier survival rate was 62.5% in ViV versus 49.5% for ViR (P<0.001). Mean gradient across the mitral valve postprocedure was 5.7±2.8 mmHg (≥5 mmHg; 61.4% of patients). Significant residual MS occurred in 8.2% of the ViV and 12.0% of the ViR patients (P=0.09). Significant residual MR was more common in ViR patients (16.6% versus 3.1%; P<0.001) and was associated with lower survival at 4 years (35.1% versus 61.6%; P=0.02). The rates of Mitral Valve Academic Research Consortium-defined device success were low for both procedures (39.4% total; 32.0% ViR versus 41.3% ViV; P=0.01), mostly related to having postprocedural mean gradient ≥5 mmHg. Correlates for residual MS were smaller true internal diameter, younger age, and larger body mass index. The only correlate for residual MR was ViR. Significant residual MS (subhazard ratio, 4.67; 95% CI, 1.74-12.56; P=0.002) and significant residual MR (subha
Published: 2021

33. Transcatheter Aortic Valve Replacement With the LOTUS Edge System:Early European Experience

Author: Armario, Xavier, Rosseel, Liesbeth, Kharbanda, Rajesh, Khogali, Saib, Abdel-Wahab, Mohamed, Van Mieghem, Nicolas M., Tchétché, Didier, Dumonteil, Nicolas, De Backer, Ole, Cotton, James, McGrath, Brian, Balakrishnan, Deepu, Ali, Noman, Farhan, Serdar, Joseph, Jubin, Charbonnier, Gaetan, Okuno, Taishi, McHugh, Fiachra, Hildick-Smith, David, Gilgen, Nicole, Hokken, Thijmen, Spence, Mark S., Frerker, Christian, Angelillis, Marco, Grygier, Marek, Cockburn, James, Bjursten, Henrik, Jeger, Raban V., Teles, Rui, Petronio, Anna S., Pilgrim, Thomas, Sinning, Jan Malte, Nickenig, Georg, Søndergaard, Lars, Blackman, Daniel J., Mylotte, Darren, Armario, Xavier, Rosseel, Liesbeth, Kharbanda, Rajesh, Khogali, Saib, Abdel-Wahab, Mohamed, Van Mieghem, Nicolas M., Tchétché, Didier, Dumonteil, Nicolas, De Backer, Ole, Cotton, James, McGrath, Brian, Balakrishnan, Deepu, Ali, Noman, Farhan, Serdar, Joseph, Jubin, Charbonnier, Gaetan, Okuno, Taishi, McHugh, Fiachra, Hildick-Smith, David, Gilgen, Nicole, Hokken, Thijmen, Spence, Mark S., Frerker, Christian, Angelillis, Marco, Grygier, Marek, Cockburn, James, Bjursten, Henrik, Jeger, Raban V., Teles, Rui, Petronio, Anna S., Pilgrim, Thomas, Sinning, Jan Malte, Nickenig, Georg, Søndergaard, Lars, Blackman, Daniel J., and Mylotte, Darren
Abstract: Objectives: The aim of this study was to evaluate the short-term safety and efficacy of transcatheter aortic valve replacement (TAVR) with the LOTUS Edge system. Background: The LOTUS Edge system was commercially re-released in April 2019. The authors report the first European experience with this device. Methods: A multicenter, single-arm, retrospective registry was initiated to evaluate short-term clinical outcomes. Included cases are the first experience with this device and new implantation technique in Europe. Clinical, echocardiographic, and computed tomographic data were analyzed. Endpoints were defined according to Valve Academic Research Consortium-2 and were site reported. Results: Between April and November 2019, 286 consecutive patients undergoing TAVR with the LOTUS Edge system at 18 European centers were included. The mean age and Society of Thoracic Surgeons score were 81.2 ± 6.9 years and 5.2 ± 5.4%, respectively. Nearly one-half of all patients (47.9%) were considered to have complex anatomy. Thirty-day major adverse events included death (2.4% [n = 7]) and stroke (3.5% [n = 10]). After TAVR, the mean aortic valve area was 1.9 ± 0.9 cm2, and the mean transvalvular gradient was 11.9 ± 5.7 mm Hg. None or trace paravalvular leak (PVL) occurred in 84.4% and moderate PVL in 2.0%. There were no cases of severe PVL. New permanent pacemaker (PPM) implantation was required in 25.9% among all patients and 30.8% among PPM-naive patients. Conclusions: Early experience with the LOTUS Edge system demonstrated satisfactory short-term safety and efficacy, favorable hemodynamic data, and very low rates of PVL in an anatomically complex cohort. New PPM implantation remained high. Further study will evaluate if increasing operator experience with the device and new implantation technique can reduce the incidence of PPM implantation.
Published: 2021

34. Permanent Pacemaker Implantation Following Valve-in-Valve Transcatheter Aortic Valve Replacement:VIVID Registry

Author: Alperi, Alberto, Rodés-Cabau, Josep, Simonato, Matheus, Tchetche, Didier, Charbonnier, Gaetan, Ribeiro, Henrique B., Latib, Azeem, Montorfano, Matteo, Barbanti, Marco, Bleiziffer, Sabine, Redfors, Björn, Abdel-Wahab, Mohamed, Allali, Abdelhakim, Bruschi, Giuseppe, Napodano, Massimo, Agrifoglio, Marco, Petronio, Anna Sonia, Giannini, Cristina, Chan, Albert, Kornowski, Ran, Pravda, Nili Schamroth, Adam, Matti, Iadanza, Alessandro, Noble, Stephane, Chatfield, Andrew, Erlebach, Magdalena, Kempfert, Jörg, Ubben, Timm, Wijeysundera, Harindra, Seiffert, Moritz, Pilgrim, Thomas, Kim, Won Keun, Testa, Luca, Hildick-Smith, David, Nerla, Roberto, Fiorina, Claudia, Brinkmann, Christina, Conzelmann, Lars, Champagnac, Didier, Saia, Francesco, Nissen, Henrik, Amrane, Hafid, Whisenant, Brian, Shamekhi, Jasmin, Søndergaard, Lars, Webb, John G., Dvir, Danny, Alperi, Alberto, Rodés-Cabau, Josep, Simonato, Matheus, Tchetche, Didier, Charbonnier, Gaetan, Ribeiro, Henrique B., Latib, Azeem, Montorfano, Matteo, Barbanti, Marco, Bleiziffer, Sabine, Redfors, Björn, Abdel-Wahab, Mohamed, Allali, Abdelhakim, Bruschi, Giuseppe, Napodano, Massimo, Agrifoglio, Marco, Petronio, Anna Sonia, Giannini, Cristina, Chan, Albert, Kornowski, Ran, Pravda, Nili Schamroth, Adam, Matti, Iadanza, Alessandro, Noble, Stephane, Chatfield, Andrew, Erlebach, Magdalena, Kempfert, Jörg, Ubben, Timm, Wijeysundera, Harindra, Seiffert, Moritz, Pilgrim, Thomas, Kim, Won Keun, Testa, Luca, Hildick-Smith, David, Nerla, Roberto, Fiorina, Claudia, Brinkmann, Christina, Conzelmann, Lars, Champagnac, Didier, Saia, Francesco, Nissen, Henrik, Amrane, Hafid, Whisenant, Brian, Shamekhi, Jasmin, Søndergaard, Lars, Webb, John G., and Dvir, Danny
Abstract: Background: Permanent pacemaker implantation (PPI) remains one of the main drawbacks of transcatheter aortic valve replacement (TAVR), but scarce data exist on PPI after valve-in-valve (ViV) TAVR, particularly with the use of newer-generation transcatheter heart valves (THVs). Objectives: The goal of this study was to determine the incidence, factors associated with, and clinical impact of PPI in a large series of ViV-TAVR procedures. Methods: Data were obtained from the multicenter VIVID Registry and included the main baseline and procedural characteristics, in-hospital and late (median follow-up: 13 months [interquartile range: 3 to 41 months]) outcomes analyzed according to the need of periprocedural PPI. All THVs except CoreValve, Cribier-Edwards, Sapien, and Sapien XT were considered to be new-generation THVs. Results: A total of 1,987 patients without prior PPI undergoing ViV-TAVR from 2007 to 2020 were included. Of these, 128 patients (6.4%) had PPI after TAVR, with a significant decrease in the incidence of PPI with the use of new-generation THVs (4.7% vs. 7.4%; p = 0.017), mainly related to a reduced PPI rate with the Evolut R/Pro versus CoreValve (3.7% vs. 9.0%; p = 0.002). There were no significant differences in PPI rates between newer-generation balloon- and self-expanding THVs (6.1% vs. 3.9%; p = 0.18). In the multivariable analysis, older age (odds ratio [OR]: 1.05 for each increase of 1 year; 95% confidence interval [CI]: 1.02 to 1.07; p = 0.001), larger THV size (OR: 1.10; 95% CI: 1.01 to 1.20; p = 0.02), and previous right bundle branch block (OR: 2.04; 95% CI: 1.00 to 4.17; p = 0.05) were associated with an increased risk of PPI. There were no differences in 30-day mortality between the PPI (4.7%) and no-PPI (2.7%) groups (p = 0.19), but PPI patients exhibited a trend toward higher mortality risk at follow-up (hazard ratio: 1.39; 95% CI: 1.02 to 1.91; p = 0.04; p = 0.08 after adjusting for age differences between groups). Conclusions: In a cont
Published: 2021

35. Threshold for calcium volume evaluation in patients with aortic valve stenosis:correlation with Agatston score

Author: Angelillis, Marco, Costa, Giulia, De Backer, Ole, Mochi, Veronica, Christou, Andrea, Giannini, Cristina, Spontoni, Paolo, De Carlo, Marco, Søndergaard, Lars, Miccoli, Mario, Petronio, Anna S, Angelillis, Marco, Costa, Giulia, De Backer, Ole, Mochi, Veronica, Christou, Andrea, Giannini, Cristina, Spontoni, Paolo, De Carlo, Marco, Søndergaard, Lars, Miccoli, Mario, and Petronio, Anna S
Abstract: BACKGROUND: The evaluation of aortic valve calcium burden is important when planning for transcatheter aortic valve implantation (TAVI). Although a robust golden standard methodology is available for calcium evaluation on noncontrast-enhanced (NCE) computed tomographic (CT) series, a standard reference for calcium assessment on contrast-enhanced CT series is currently lacking.METHODS: Two hundred and forty-four preprocedural CT scans from patients who had received TAVI were analysed. We correlated the aortic calcium volumes obtained on CE series at three thresholds [450, 850, and 'probe + 100' Hounsfield Units (HU)] with the Agatston score obtained on NCE scans. A subgroup analysis was performed taking into account the contrast enhancement of the left ventricular outflow tract (LVOT), with a prespecified cut-off of 300 HU.RESULTS: The overall population analysis showed higher correlation with the Agatston score using the 850 HU threshold (r = 0.45, P < 0.0001); no correlation was found with the 450 HU threshold, whilst the 'probe + 100' HU threshold showed a weaker correlation (r = 0.30, P < 0.0001). In patients with LVOT enhancement less than 300 HU, 450 HU showed the highest accuracy in calcium identification (r = 0.70, P < 0.0001), whereas in patients with LVOT enhancement of at least 300 HU, the most accurate threshold was 850 HU (r = 0.46, P < 0.0001).CONCLUSION: The thresholds for correct calcium identification using the automatic 3Mensio software depend on the contrast enhancement of aortic and cardiac structures, which can be estimated by measuring the HU in the LVOT. In patients with LVOT HU of less than 300, the correct threshold to be set in the software is 450 HU, whereas in patients with LVOT HU of at least 300 the correct threshold is 850 HU.
Published: 2021

36. 2020 ESC Guidelines for the management of adult congenital heart disease

Author: Baumgartner, Helmut, de Backer, Julie, Babu-Narayan, Sonya V., Budts, Werner, Chessa, Massimo, Diller, Gerhard Paul, Iung, Bernard, Kluin, Jolanda, Lang, Irene M., Meijboom, Folkert, Moons, Philip, Mulder, Barbara J.M., Oechslin, Erwin, Roos-Hesselink, Jolien W., Schwerzmann, Markus, Sondergaard, Lars, Zeppenfeld, Katja, Windecker, Stephan, Aboyans, Victor, Baigent, Colin, Collet, Jean Philippe, Dean, Veronica, Delgado, Victoria, Fitzsimons, Donna, Gale, Chris P., Grobbee, Diederick E., Halvorsen, Sigrun, Hindricks, Gerhard, Jüni, Peter, Katus, Hugo A., Landmesser, Ulf, Leclercq, Christophe, Lettino, Maddalena, Lewis, Basil S., Merkely, Béla, Mueller, Christian, Petersen, Steffen E., Petronio, Anna Sonia, Richter, Dimitrios J., Roffi, Marco, Shlyakhto, Evgeny, Simpson, Iain A., Sousa-Uva, Miguel, Touyz, Rhian M., Baumgartner, Helmut, de Backer, Julie, Babu-Narayan, Sonya V., Budts, Werner, Chessa, Massimo, Diller, Gerhard Paul, Iung, Bernard, Kluin, Jolanda, Lang, Irene M., Meijboom, Folkert, Moons, Philip, Mulder, Barbara J.M., Oechslin, Erwin, Roos-Hesselink, Jolien W., Schwerzmann, Markus, Sondergaard, Lars, Zeppenfeld, Katja, Windecker, Stephan, Aboyans, Victor, Baigent, Colin, Collet, Jean Philippe, Dean, Veronica, Delgado, Victoria, Fitzsimons, Donna, Gale, Chris P., Grobbee, Diederick E., Halvorsen, Sigrun, Hindricks, Gerhard, Jüni, Peter, Katus, Hugo A., Landmesser, Ulf, Leclercq, Christophe, Lettino, Maddalena, Lewis, Basil S., Merkely, Béla, Mueller, Christian, Petersen, Steffen E., Petronio, Anna Sonia, Richter, Dimitrios J., Roffi, Marco, Shlyakhto, Evgeny, Simpson, Iain A., Sousa-Uva, Miguel, and Touyz, Rhian M.
Published: 2021

37. Prevalence, predictors, and outcomes of patient prosthesis mismatch in women undergoing TAVI for severe aortic stenosis:Insights from the WIN-TAVI registry

Author: Panoulas, Vasileios F., Chandrasekhar, Jaya, Busi, Gherardo, Ruparelia, Neil, Zhang, Zhongjie, Mehilli, Julinda, Sartori, Samantha, Lefèvre, Thierre, Presbitero, Patrizia, Capranzano, Piera, Tchetche, Didier, Iadanza, Alessandro, Sardella, Gennaro, Van Mieghem, Nicolas M., Meliga, Emanuele, Dumonteil, Nicolas, Fraccaro, Chiara, Trabattoni, Daniela, Sharma, Samin, Ferrer-Gracia, Maria Cruz, Naber, Christoph K., Kievit, Peter C., Snyder, Clayton, Sutaria, Nilesh, Sen, Sayan, Malik, Iqbal S., Morice, Marie Claude, Nihoyannopoulos, Petros, Petronio, Anna Sonia, Mehran, Roxana, Chieffo, Alaide, Mikhail, Ghada W., Panoulas, Vasileios F., Chandrasekhar, Jaya, Busi, Gherardo, Ruparelia, Neil, Zhang, Zhongjie, Mehilli, Julinda, Sartori, Samantha, Lefèvre, Thierre, Presbitero, Patrizia, Capranzano, Piera, Tchetche, Didier, Iadanza, Alessandro, Sardella, Gennaro, Van Mieghem, Nicolas M., Meliga, Emanuele, Dumonteil, Nicolas, Fraccaro, Chiara, Trabattoni, Daniela, Sharma, Samin, Ferrer-Gracia, Maria Cruz, Naber, Christoph K., Kievit, Peter C., Snyder, Clayton, Sutaria, Nilesh, Sen, Sayan, Malik, Iqbal S., Morice, Marie Claude, Nihoyannopoulos, Petros, Petronio, Anna Sonia, Mehran, Roxana, Chieffo, Alaide, and Mikhail, Ghada W.
Abstract: Objective: To evaluate the incidence, predictors and outcomes of female patients with patient-prosthesis mismatch (PPM) following transcatheter aortic valve intervention (TAVI) for severe aortic stenosis (AS). Background: Female AS TAVI recipients have a significantly lower mortality than surgical aortic valve replacement (SAVR) recipients, which could be attributed to the potentially lower PPM rates. TAVI has been associated with lower rates of PPM compared to SAVR. PPM in females post TAVI has not been investigated to date. Methods: The WIN-TAVI (Women's INternational Transcatheter Aortic Valve Implantation) registry is a multicenter registry of women undergoing TAVR for severe symptomatic AS. Two hundred and fifty patients with detailed periprocedural and follow-up echocardiographic investigations were included in the WIN-TAVI echocardiographic sub-study. PPM was defined as per European guidelines stratified by the presence of obesity. Results: The incidence of PPM in our population was 32.8%. Patients with PPM had significantly higher BMI (27.4 ± 6.1 vs. 25.2 ± 5.0, p =.002), smaller sized valves implanted (percentage of TAVI ≤23 mm 61% vs. 29.2%, PPM vs. no PPM, p <.001) and were more often treated with balloon expandable valves (48.3 vs. 32.5%, p <.001) rather than self expanding ones (26.3 vs. 52.8%, <.001). BMI (OR = 1.08; 95%CI 1.02–1.14, p =.011) and valve size ≤23 mm (OR = 3.00 95%CI 1.14–7.94, p =.027) were the only independent predictors of PPM. There was no significant interaction between valve size and valve type (p =.203). No significant differences were observed in 1-year mortality or major adverse cardiovascular events. Conclusions: PPM in females undergoing TAVI occurs in one third of patients. BMI and valve size ≤23 mm are independent predictors. Larger registries are required to determine the impact of PPM on future clinical outcomes.
Published: 2021

38. Impact of High Body Mass Index on Vascular and Bleeding Complications After Transcatheter Aortic Valve Implantation

Author: Berti, Sergio, Bartorelli, Antonio L, Koni, Endrin, Giordano, Arturo, Petronio, Anna S, Iadanza, Alessandro, Bedogni, Francesco, Reimers, Bernard, Spaccarotella, Carmen, Trani, Carlo, Attisano, Tiziana, Sardella, Gennaro, Bonmassari, Roberto, Medda, Massimo, Sherwood, Matthew W, Tomai, Fabrizio, Navarese, Eliano P, Trani, Carlo (ORCID:0000-0001-9777-013X), Berti, Sergio, Bartorelli, Antonio L, Koni, Endrin, Giordano, Arturo, Petronio, Anna S, Iadanza, Alessandro, Bedogni, Francesco, Reimers, Bernard, Spaccarotella, Carmen, Trani, Carlo, Attisano, Tiziana, Sardella, Gennaro, Bonmassari, Roberto, Medda, Massimo, Sherwood, Matthew W, Tomai, Fabrizio, Navarese, Eliano P, and Trani, Carlo (ORCID:0000-0001-9777-013X)
Abstract: N/A
Published: 2021

39. EAPCI Core Curriculum for Percutaneous Cardiovascular Interventions (2020):Committee for Education and Training European Association of Percutaneous Cardiovascular Interventions (EAPCI). A branch of the European Society of Cardiology

Author: Van Belle, Eric, Teles, Rui C., Pyxaras, Stylianos A., Kalpak, Oliver, Johnson, Thomas, Barbash, Israel Moshe, De Luca, Giuseppe, Kostov, Jorgo, Parma, Radoslaw, Vincent, Flavien, Brugaletta, Salvatore, Debry, Nicolas, Toth, Gabor G., Ghazzal, Ziyad, Deharo, Pierre, Milasinovic, Dejan, Kaspar, Klaus, Saia, Francesco, Mauri, Josepa, Kammler, Jürgen, Muir, Douglas, O'Connor, Stephen, Mehilli, Julinda, Thiele, Holger, Weilenmann, Daniel, Witt, Nils, Joshi, Francis, Kharbanda, Rajesh, Piroth, Zsolt, Wojakowski, Wojciech, Geppert, Alexander, Di Gioia, Giuseppe, Pires-Morais, Gustavo, Petronio, Anna Sonia, Estévez-Loureiro, Rodrigo, Ruzsa, Zoltan, Kefer, Joelle, Kunadian, Vijay, Van Mieghem, Nicolas, Windecker, Stephan, Baumbach, Andreas, Haude, Michael, Dudek, Dariusz, Van Belle, Eric, Teles, Rui C., Pyxaras, Stylianos A., Kalpak, Oliver, Johnson, Thomas, Barbash, Israel Moshe, De Luca, Giuseppe, Kostov, Jorgo, Parma, Radoslaw, Vincent, Flavien, Brugaletta, Salvatore, Debry, Nicolas, Toth, Gabor G., Ghazzal, Ziyad, Deharo, Pierre, Milasinovic, Dejan, Kaspar, Klaus, Saia, Francesco, Mauri, Josepa, Kammler, Jürgen, Muir, Douglas, O'Connor, Stephen, Mehilli, Julinda, Thiele, Holger, Weilenmann, Daniel, Witt, Nils, Joshi, Francis, Kharbanda, Rajesh, Piroth, Zsolt, Wojakowski, Wojciech, Geppert, Alexander, Di Gioia, Giuseppe, Pires-Morais, Gustavo, Petronio, Anna Sonia, Estévez-Loureiro, Rodrigo, Ruzsa, Zoltan, Kefer, Joelle, Kunadian, Vijay, Van Mieghem, Nicolas, Windecker, Stephan, Baumbach, Andreas, Haude, Michael, and Dudek, Dariusz
Abstract: The proposed 2020 Core Curriculum for Percutaneous Cardiovascular Interventions aims to provide an updated European consensus that defines the level of experience and knowledge in the field of percutaneous cardiovascular intervention (PCI). It promotes homogenous education and training programmes among countries, and is the cornerstone of the new EAPCI certification, designed to support the recognition of competencies at the European level and the free movement of certified specialists in the European Community. It is based on a thorough review of the ESC guidelines and of the EAPCI textbook on percutaneous interventional cardiovascular medicine. The structure of the current core curriculum evolved from previous EAPCI core curricula and from the "2013 core curriculum of the general cardiologist"to follow the current ESC recommendations for core curricula. In most subject areas, there was a wide - if not unanimous - consensus among the task force members on the training required for the interventional cardiologist of the future. The document recommends that acquisition of competence in interventional cardiology requires at least two years of postgraduate training, in addition to four years devoted to cardiology. The first part of the curriculum covers general aspects of training and is followed by a comprehensive description of the specific components in 54 chapters. Each of the chapters includes statements of the objectives, and is further subdivided into the required knowledge, skills, behaviours, and attitudes.
Published: 2021

40. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease

Author: Ten Berg, Jurrien, Sibbing, Dirk, Rocca, Bianca, Van Belle, Eric, Chevalier, Bernard, Collet, Jean-Philippe, Dudek, Dariusz, Gilard, Martine, Gorog, Diana A, Grapsa, Julia, Grove, Erik Lerkevang, Lancellotti, Patrizio, Petronio, Anna Sonia, Rubboli, Andrea, Torracca, Lucia, Vilahur, Gemma, Witkowski, Adam, Mehilli, Julinda, Rocca, Bianca (ORCID:0000-0001-8304-6423), Ten Berg, Jurrien, Sibbing, Dirk, Rocca, Bianca, Van Belle, Eric, Chevalier, Bernard, Collet, Jean-Philippe, Dudek, Dariusz, Gilard, Martine, Gorog, Diana A, Grapsa, Julia, Grove, Erik Lerkevang, Lancellotti, Patrizio, Petronio, Anna Sonia, Rubboli, Andrea, Torracca, Lucia, Vilahur, Gemma, Witkowski, Adam, Mehilli, Julinda, and Rocca, Bianca (ORCID:0000-0001-8304-6423)
Abstract: Transcatheter aortic valve implantation (TAVI) is effective in older patients with symptomatic severe aortic stenosis, while the indication has recently broadened to younger patients at lower risk. Although thromboembolic and bleeding complications after TAVI have decreased over time, such adverse events are still common. The recommendations of the latest 2017 ESC/EACTS Guidelines for the management of valvular heart disease on antithrombotic therapy in patients undergoing TAVI are mostly based on expert opinion. Based on recent studies and randomized controlled trials, this viewpoint document provides updated therapeutic insights in antithrombotic treatment during and after TAVI.
Published: 2021

41. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS) : The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)

Author: Konstantinides, Stavros V., Meyer, Guy, Bueno, Hector, Galié, Nazzareno, Gibbs, J. Simon R., Ageno, Walter, Agewall, Stefan, Almeida, Ana G., Andreotti, Felicita, Barbato, Emanuele, Baumbach, Andreas, Beygui, Farzin, Carlsen, Jørn, De Carlo, Marco, Delcroix, Marion, Subias, Pilar Escribano, Gaine, Sean, Goldhaber, Samuel Z., Gopalan, Deepa, Habib, Gilbert, Jenkins, David, Kjellström, Barbro, Lainscak, Mitja, Lee, Geraldine, Le Gal, Grégoire, Messas, Emmanuel, Morais, Joao, Piepoli, Massimo Francesco, Price, Susanna, Salvi, Aldo, Sanchez, Olivier, Stortecky, Stefan, Thielmann, Matthias, Noordegraaf, Anton Vonk, Becattini, Cecilia, Bueno, Héctor, Geersing, Geert Jan, Harjola, Veli Pekka, Huisman, Menno V., Humbert, Marc, Jennings, Catriona Sian, Jiménez, David, Kucher, Nils, Lang, Irene Marthe, Lankeit, Mareike, Lorusso, Roberto, Mazzolai, Lucia, Meneveau, Nicolas, Áinle, Fionnuala Ní, Prandoni, Paolo, Pruszczyk, Piotr, Righini, Marc, Torbicki, Adam, Van Belle, Eric, Zamorano, José Luis, Windecker, Stephan, Aboyans, Victor, Baigent, Colin, Collet, Jean Philippe, Dean, Veronica, Delgado, Victoria, Fitzsimons, Donna, Gale, Chris P., Grobbee, Diederick E., Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo A., Landmesser, Ulf, Leclercq, Christophe, Lettino, Maddalena, Lewis, Basil S., Merkely, Bela, Mueller, Christian, Petersen, Steffen E., Petronio, Anna Sonia, Richter, Dimitrios J., Roffi, Marco, Shlyakhto, Evgeny, Simpson, Iain A., Sousa-Uva, Miguel, Touyz, Rhian M., Hammoudi, Naima, Hayrapetyan, Hamlet, Mascherbauer, Julia, Ibrahimov, Firdovsi, Polonetsky, Oleg, Lancellotti, Patrizio, Tokmakova, Mariya, Skoric, Bosko, Michaloliakos, Ioannis, Hutyra, Martin, Mellemkjaer, Søren, Mansour, Mostafa, Reinmets, Julia, Jääskeläinen, Pertti, Angoulvant, Denis, Bauersachs, Johann, Giannakoulas, George, Zima, Endre, Vizza, Carmine Dario, Sugraliyev, Akhmetzhan, Bytyçi, Ibadete, Maca, Aija, Ereminiene, Egle, Huijnen, Steve, Xuereb, Robert, Diaconu, Nadejda, Bulatovic, Nebojsa, Asfalou, Ilyasse, Bosevski, Marijan, Halvorsen, Sigrun, Sobkowicz, Bozena, Ferreira, Daniel, Petris, Antoniu Octavian, Moiseeva, Olga, Zavatta, Marco, Obradovic, Slobodan, Šimkova, Iveta, Radsel, Peter, Ibanez, Borja, Wikström, Gerhard, Aujesky, Drahomir, Kaymaz, Cihangir, Parkhomenko, Alexander, Pepke-Zaba, Joanna, Konstantinides, Stavros V., Meyer, Guy, Bueno, Hector, Galié, Nazzareno, Gibbs, J. Simon R., Ageno, Walter, Agewall, Stefan, Almeida, Ana G., Andreotti, Felicita, Barbato, Emanuele, Baumbach, Andreas, Beygui, Farzin, Carlsen, Jørn, De Carlo, Marco, Delcroix, Marion, Subias, Pilar Escribano, Gaine, Sean, Goldhaber, Samuel Z., Gopalan, Deepa, Habib, Gilbert, Jenkins, David, Kjellström, Barbro, Lainscak, Mitja, Lee, Geraldine, Le Gal, Grégoire, Messas, Emmanuel, Morais, Joao, Piepoli, Massimo Francesco, Price, Susanna, Salvi, Aldo, Sanchez, Olivier, Stortecky, Stefan, Thielmann, Matthias, Noordegraaf, Anton Vonk, Becattini, Cecilia, Bueno, Héctor, Geersing, Geert Jan, Harjola, Veli Pekka, Huisman, Menno V., Humbert, Marc, Jennings, Catriona Sian, Jiménez, David, Kucher, Nils, Lang, Irene Marthe, Lankeit, Mareike, Lorusso, Roberto, Mazzolai, Lucia, Meneveau, Nicolas, Áinle, Fionnuala Ní, Prandoni, Paolo, Pruszczyk, Piotr, Righini, Marc, Torbicki, Adam, Van Belle, Eric, Zamorano, José Luis, Windecker, Stephan, Aboyans, Victor, Baigent, Colin, Collet, Jean Philippe, Dean, Veronica, Delgado, Victoria, Fitzsimons, Donna, Gale, Chris P., Grobbee, Diederick E., Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo A., Landmesser, Ulf, Leclercq, Christophe, Lettino, Maddalena, Lewis, Basil S., Merkely, Bela, Mueller, Christian, Petersen, Steffen E., Petronio, Anna Sonia, Richter, Dimitrios J., Roffi, Marco, Shlyakhto, Evgeny, Simpson, Iain A., Sousa-Uva, Miguel, Touyz, Rhian M., Hammoudi, Naima, Hayrapetyan, Hamlet, Mascherbauer, Julia, Ibrahimov, Firdovsi, Polonetsky, Oleg, Lancellotti, Patrizio, Tokmakova, Mariya, Skoric, Bosko, Michaloliakos, Ioannis, Hutyra, Martin, Mellemkjaer, Søren, Mansour, Mostafa, Reinmets, Julia, Jääskeläinen, Pertti, Angoulvant, Denis, Bauersachs, Johann, Giannakoulas, George, Zima, Endre, Vizza, Carmine Dario, Sugraliyev, Akhmetzhan, Bytyçi, Ibadete, Maca, Aija, Ereminiene, Egle, Huijnen, Steve, Xuereb, Robert, Diaconu, Nadejda, Bulatovic, Nebojsa, Asfalou, Ilyasse, Bosevski, Marijan, Halvorsen, Sigrun, Sobkowicz, Bozena, Ferreira, Daniel, Petris, Antoniu Octavian, Moiseeva, Olga, Zavatta, Marco, Obradovic, Slobodan, Šimkova, Iveta, Radsel, Peter, Ibanez, Borja, Wikström, Gerhard, Aujesky, Drahomir, Kaymaz, Cihangir, Parkhomenko, Alexander, and Pepke-Zaba, Joanna
Published: 2020

42. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS) : The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)

Author: Konstantinides, Stavros V., Meyer, Guy, Bueno, Hector, Galié, Nazzareno, Gibbs, J. Simon R., Ageno, Walter, Agewall, Stefan, Almeida, Ana G., Andreotti, Felicita, Barbato, Emanuele, Baumbach, Andreas, Beygui, Farzin, Carlsen, Jørn, De Carlo, Marco, Delcroix, Marion, Subias, Pilar Escribano, Gaine, Sean, Goldhaber, Samuel Z., Gopalan, Deepa, Habib, Gilbert, Jenkins, David, Kjellström, Barbro, Lainscak, Mitja, Lee, Geraldine, Le Gal, Grégoire, Messas, Emmanuel, Morais, Joao, Piepoli, Massimo Francesco, Price, Susanna, Salvi, Aldo, Sanchez, Olivier, Stortecky, Stefan, Thielmann, Matthias, Noordegraaf, Anton Vonk, Becattini, Cecilia, Bueno, Héctor, Geersing, Geert Jan, Harjola, Veli Pekka, Huisman, Menno V., Humbert, Marc, Jennings, Catriona Sian, Jiménez, David, Kucher, Nils, Lang, Irene Marthe, Lankeit, Mareike, Lorusso, Roberto, Mazzolai, Lucia, Meneveau, Nicolas, Áinle, Fionnuala Ní, Prandoni, Paolo, Pruszczyk, Piotr, Righini, Marc, Torbicki, Adam, Van Belle, Eric, Zamorano, José Luis, Windecker, Stephan, Aboyans, Victor, Baigent, Colin, Collet, Jean Philippe, Dean, Veronica, Delgado, Victoria, Fitzsimons, Donna, Gale, Chris P., Grobbee, Diederick E., Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo A., Landmesser, Ulf, Leclercq, Christophe, Lettino, Maddalena, Lewis, Basil S., Merkely, Bela, Mueller, Christian, Petersen, Steffen E., Petronio, Anna Sonia, Richter, Dimitrios J., Roffi, Marco, Shlyakhto, Evgeny, Simpson, Iain A., Sousa-Uva, Miguel, Touyz, Rhian M., Hammoudi, Naima, Hayrapetyan, Hamlet, Mascherbauer, Julia, Ibrahimov, Firdovsi, Polonetsky, Oleg, Lancellotti, Patrizio, Tokmakova, Mariya, Skoric, Bosko, Michaloliakos, Ioannis, Hutyra, Martin, Mellemkjaer, Søren, Mansour, Mostafa, Reinmets, Julia, Jääskeläinen, Pertti, Angoulvant, Denis, Bauersachs, Johann, Giannakoulas, George, Zima, Endre, Vizza, Carmine Dario, Sugraliyev, Akhmetzhan, Bytyçi, Ibadete, Maca, Aija, Ereminiene, Egle, Huijnen, Steve, Xuereb, Robert, Diaconu, Nadejda, Bulatovic, Nebojsa, Asfalou, Ilyasse, Bosevski, Marijan, Halvorsen, Sigrun, Sobkowicz, Bozena, Ferreira, Daniel, Petris, Antoniu Octavian, Moiseeva, Olga, Zavatta, Marco, Obradovic, Slobodan, Šimkova, Iveta, Radsel, Peter, Ibanez, Borja, Wikström, Gerhard, Aujesky, Drahomir, Kaymaz, Cihangir, Parkhomenko, Alexander, Pepke-Zaba, Joanna, Konstantinides, Stavros V., Meyer, Guy, Bueno, Hector, Galié, Nazzareno, Gibbs, J. Simon R., Ageno, Walter, Agewall, Stefan, Almeida, Ana G., Andreotti, Felicita, Barbato, Emanuele, Baumbach, Andreas, Beygui, Farzin, Carlsen, Jørn, De Carlo, Marco, Delcroix, Marion, Subias, Pilar Escribano, Gaine, Sean, Goldhaber, Samuel Z., Gopalan, Deepa, Habib, Gilbert, Jenkins, David, Kjellström, Barbro, Lainscak, Mitja, Lee, Geraldine, Le Gal, Grégoire, Messas, Emmanuel, Morais, Joao, Piepoli, Massimo Francesco, Price, Susanna, Salvi, Aldo, Sanchez, Olivier, Stortecky, Stefan, Thielmann, Matthias, Noordegraaf, Anton Vonk, Becattini, Cecilia, Bueno, Héctor, Geersing, Geert Jan, Harjola, Veli Pekka, Huisman, Menno V., Humbert, Marc, Jennings, Catriona Sian, Jiménez, David, Kucher, Nils, Lang, Irene Marthe, Lankeit, Mareike, Lorusso, Roberto, Mazzolai, Lucia, Meneveau, Nicolas, Áinle, Fionnuala Ní, Prandoni, Paolo, Pruszczyk, Piotr, Righini, Marc, Torbicki, Adam, Van Belle, Eric, Zamorano, José Luis, Windecker, Stephan, Aboyans, Victor, Baigent, Colin, Collet, Jean Philippe, Dean, Veronica, Delgado, Victoria, Fitzsimons, Donna, Gale, Chris P., Grobbee, Diederick E., Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo A., Landmesser, Ulf, Leclercq, Christophe, Lettino, Maddalena, Lewis, Basil S., Merkely, Bela, Mueller, Christian, Petersen, Steffen E., Petronio, Anna Sonia, Richter, Dimitrios J., Roffi, Marco, Shlyakhto, Evgeny, Simpson, Iain A., Sousa-Uva, Miguel, Touyz, Rhian M., Hammoudi, Naima, Hayrapetyan, Hamlet, Mascherbauer, Julia, Ibrahimov, Firdovsi, Polonetsky, Oleg, Lancellotti, Patrizio, Tokmakova, Mariya, Skoric, Bosko, Michaloliakos, Ioannis, Hutyra, Martin, Mellemkjaer, Søren, Mansour, Mostafa, Reinmets, Julia, Jääskeläinen, Pertti, Angoulvant, Denis, Bauersachs, Johann, Giannakoulas, George, Zima, Endre, Vizza, Carmine Dario, Sugraliyev, Akhmetzhan, Bytyçi, Ibadete, Maca, Aija, Ereminiene, Egle, Huijnen, Steve, Xuereb, Robert, Diaconu, Nadejda, Bulatovic, Nebojsa, Asfalou, Ilyasse, Bosevski, Marijan, Halvorsen, Sigrun, Sobkowicz, Bozena, Ferreira, Daniel, Petris, Antoniu Octavian, Moiseeva, Olga, Zavatta, Marco, Obradovic, Slobodan, Šimkova, Iveta, Radsel, Peter, Ibanez, Borja, Wikström, Gerhard, Aujesky, Drahomir, Kaymaz, Cihangir, Parkhomenko, Alexander, and Pepke-Zaba, Joanna
Published: 2020

43. Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves

Author: Bleiziffer, Sabine, Simonato, Matheus, Webb, John G., Rodes-Cabau, Josep, Pibarot, Philippe, Kornowski, Ran, Windecker, Stephan, Erlebach, Magdalena, Duncan, Alison, Seiffert, Moritz, Unbehaun, Axel, Frerker, Christian, Conzelmann, Lars, Wijeysundera, Harindra, Kim, Won-Keun, Montorfano, Matteo, Latib, Azeem, Tchetche, Didier, Allali, Abdelhakim, Abdel-Wahab, Mohamed, Orvin, Katia, Stortecky, Stefan, Nissen, Henrik, Holzamer, Andreas, Urena, Marina, Testa, Luca, Agrifoglio, Marco, Whisenant, Brian, Sathananthan, Janarthanan, Napodano, Massimo, Landi, Antonio, Fiorina, Claudia, Zittermann, Armin, Veulemans, Verena, Sinning, Jan-Malte, Saia, Francesco, Brecker, Stephen, Presbitero, Patrizia, De Backer, Ole, Sondergaard, Lars, Bruschi, Giuseppe, Franco, Luis Nombela, Petronio, Anna Sonia, Barbanti, Marco, Cerillo, Alfredo, Spargias, Konstantinos, Schofer, Joachim, Cohen, Mauricio, Munoz-Garcia, Antonio, Finkelstein, Ariel, Adam, Matti, Serra, Vicenc, Teles, Rui Campante, Champagnac, Didier, Iadanza, Alessandro, Chodor, Piotr, Eggebrecht, Holger, Welsh, Robert, Caixeta, Adriano, Salizzoni, Stefano, Dager, Antonio, Auffret, Vincent, Cheema, Asim, Ubben, Timm, Ancona, Marco, Rudolph, Tanja, Gummert, Jan, Tseng, Elaine, Noble, Stephane, Bunc, Matjaz, Roberts, David, Kass, Malek, Gupta, Anuj, Leon, Martin B., Dvir, Danny, Bleiziffer, Sabine, Simonato, Matheus, Webb, John G., Rodes-Cabau, Josep, Pibarot, Philippe, Kornowski, Ran, Windecker, Stephan, Erlebach, Magdalena, Duncan, Alison, Seiffert, Moritz, Unbehaun, Axel, Frerker, Christian, Conzelmann, Lars, Wijeysundera, Harindra, Kim, Won-Keun, Montorfano, Matteo, Latib, Azeem, Tchetche, Didier, Allali, Abdelhakim, Abdel-Wahab, Mohamed, Orvin, Katia, Stortecky, Stefan, Nissen, Henrik, Holzamer, Andreas, Urena, Marina, Testa, Luca, Agrifoglio, Marco, Whisenant, Brian, Sathananthan, Janarthanan, Napodano, Massimo, Landi, Antonio, Fiorina, Claudia, Zittermann, Armin, Veulemans, Verena, Sinning, Jan-Malte, Saia, Francesco, Brecker, Stephen, Presbitero, Patrizia, De Backer, Ole, Sondergaard, Lars, Bruschi, Giuseppe, Franco, Luis Nombela, Petronio, Anna Sonia, Barbanti, Marco, Cerillo, Alfredo, Spargias, Konstantinos, Schofer, Joachim, Cohen, Mauricio, Munoz-Garcia, Antonio, Finkelstein, Ariel, Adam, Matti, Serra, Vicenc, Teles, Rui Campante, Champagnac, Didier, Iadanza, Alessandro, Chodor, Piotr, Eggebrecht, Holger, Welsh, Robert, Caixeta, Adriano, Salizzoni, Stefano, Dager, Antonio, Auffret, Vincent, Cheema, Asim, Ubben, Timm, Ancona, Marco, Rudolph, Tanja, Gummert, Jan, Tseng, Elaine, Noble, Stephane, Bunc, Matjaz, Roberts, David, Kass, Malek, Gupta, Anuj, Leon, Martin B., and Dvir, Danny
Abstract: Aims Due to bioprosthetic valve degeneration, aortic valve-in-valve (ViV) procedures are increasingly performed. There are no data on long-term outcomes after aortic ViV. Our aim was to perform a large-scale assessment of long-term survival and reintervention after aortic ViV. Methods and results A total of 1006 aortic ViV procedures performed more than 5 years ago [mean age 77.7 +/- 9.7 years; 58.8% mate; median STS-PROM score 7.3% (4.2-12.0)] were included in the analysis. Patients were treated with Medtronic self-expandable valves (CoreVatve/Evolut, Medtronic Inc., Minneapolis, MN, USA) (n = 523, 52.0%), Edwards balloo-nexpandable valves (EBEV, SAPIEN/SAPIEN XT/SAPIEN 3, Edwards Lifesciences, Irvine, CA, USA) (n=435, 43.2%), and other devices (n =48, 4.8%). Survival was tower at 8 years in patients with small-failed bioprostheses [internal diameter (ID) < 20 mm] compared with those with large-failed bioprostheses (ID > 20 mm) (33.2% vs. 40.5%, P= 0.01). Independent correlates for mortality included smaller-failed bioprosthetic valves [hazard ratio (HR) 1.07 (95% confidence interval (CI) 1.02-1.13)], age [HR 1.21 (95% CI 1.01-1.45)], and non-transfemoral access [HR 1.43 (95% CI 1.11-1.84)]. There were 40 reinterventions after ViV. Independent correlates for all-cause reintervention included pre-existing severe prosthesis-patient mismatch [subhazard ratio (SHR) 4.34 (95% CI 1.31-14.39)], device malposition [SHR 3.75 (95% CI 1.36-10.35)], EBEV [SHR 3.34 (95% CI 1.26-8.85)], and age [SHR 0.59 (95% CI 0.44-0.78)]. Conclusions: The size of the original failed valve may influence long-term mortality, and the type of the transcatheter valve may influence the need for reintervention after aortic ViV. [GRAPHICS] .
Published: 2020

44. Transcatheter Aortic Valve Replacement With the LOTUS Edge System: Early European Experience

Author: Armario, Xavier, Rosseel, Liesbeth, Kharbanda, Rajesh, Khogali, Saib, Abdel-Wahab, Mohamed, Van Mieghem, Nicolas, Tchetche, Didier, Dumonteil, Nicolas, De Backer, Ole, Cotton, James, McGrath, Brian, Balakrishnan, Deepu, Ali, Noman, Farhan, Serdar, Joseph, Jubin, Charbonnier, Gaetan, Okuno, Taishi, McHugh, Fiachra, Hildick-Smith, David, Gilgen, Nicole, Frerker, Christian, Angelillis, Marco, Grygier, Marek, Cockburn, James, Bjursten, Henrik, Teles, Rui, Petronio, Anna Sonia, Pilgrim, Thomas, Sinning, Jan-Malte, Nickenig, Georg, Sondergaard, Lars, Mylotte, Darren, Armario, Xavier, Rosseel, Liesbeth, Kharbanda, Rajesh, Khogali, Saib, Abdel-Wahab, Mohamed, Van Mieghem, Nicolas, Tchetche, Didier, Dumonteil, Nicolas, De Backer, Ole, Cotton, James, McGrath, Brian, Balakrishnan, Deepu, Ali, Noman, Farhan, Serdar, Joseph, Jubin, Charbonnier, Gaetan, Okuno, Taishi, McHugh, Fiachra, Hildick-Smith, David, Gilgen, Nicole, Frerker, Christian, Angelillis, Marco, Grygier, Marek, Cockburn, James, Bjursten, Henrik, Teles, Rui, Petronio, Anna Sonia, Pilgrim, Thomas, Sinning, Jan-Malte, Nickenig, Georg, Sondergaard, Lars, and Mylotte, Darren
Published: 2020

45. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS) : The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)

Author: Konstantinides, Stavros V., Meyer, Guy, Bueno, Hector, Galié, Nazzareno, Gibbs, J. Simon R., Ageno, Walter, Agewall, Stefan, Almeida, Ana G., Andreotti, Felicita, Barbato, Emanuele, Baumbach, Andreas, Beygui, Farzin, Carlsen, Jørn, De Carlo, Marco, Delcroix, Marion, Subias, Pilar Escribano, Gaine, Sean, Goldhaber, Samuel Z., Gopalan, Deepa, Habib, Gilbert, Jenkins, David, Kjellström, Barbro, Lainscak, Mitja, Lee, Geraldine, Le Gal, Grégoire, Messas, Emmanuel, Morais, Joao, Piepoli, Massimo Francesco, Price, Susanna, Salvi, Aldo, Sanchez, Olivier, Stortecky, Stefan, Thielmann, Matthias, Noordegraaf, Anton Vonk, Becattini, Cecilia, Bueno, Héctor, Geersing, Geert Jan, Harjola, Veli Pekka, Huisman, Menno V., Humbert, Marc, Jennings, Catriona Sian, Jiménez, David, Kucher, Nils, Lang, Irene Marthe, Lankeit, Mareike, Lorusso, Roberto, Mazzolai, Lucia, Meneveau, Nicolas, Áinle, Fionnuala Ní, Prandoni, Paolo, Pruszczyk, Piotr, Righini, Marc, Torbicki, Adam, Van Belle, Eric, Zamorano, José Luis, Windecker, Stephan, Aboyans, Victor, Baigent, Colin, Collet, Jean Philippe, Dean, Veronica, Delgado, Victoria, Fitzsimons, Donna, Gale, Chris P., Grobbee, Diederick E., Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo A., Landmesser, Ulf, Leclercq, Christophe, Lettino, Maddalena, Lewis, Basil S., Merkely, Bela, Mueller, Christian, Petersen, Steffen E., Petronio, Anna Sonia, Richter, Dimitrios J., Roffi, Marco, Shlyakhto, Evgeny, Simpson, Iain A., Sousa-Uva, Miguel, Touyz, Rhian M., Hammoudi, Naima, Hayrapetyan, Hamlet, Mascherbauer, Julia, Ibrahimov, Firdovsi, Polonetsky, Oleg, Lancellotti, Patrizio, Tokmakova, Mariya, Skoric, Bosko, Michaloliakos, Ioannis, Hutyra, Martin, Mellemkjaer, Søren, Mansour, Mostafa, Reinmets, Julia, Jääskeläinen, Pertti, Angoulvant, Denis, Bauersachs, Johann, Giannakoulas, George, Zima, Endre, Vizza, Carmine Dario, Sugraliyev, Akhmetzhan, Bytyçi, Ibadete, Maca, Aija, Ereminiene, Egle, Huijnen, Steve, Xuereb, Robert, Diaconu, Nadejda, Bulatovic, Nebojsa, Asfalou, Ilyasse, Bosevski, Marijan, Halvorsen, Sigrun, Sobkowicz, Bozena, Ferreira, Daniel, Petris, Antoniu Octavian, Moiseeva, Olga, Zavatta, Marco, Obradovic, Slobodan, Šimkova, Iveta, Radsel, Peter, Ibanez, Borja, Wikström, Gerhard, Aujesky, Drahomir, Kaymaz, Cihangir, Parkhomenko, Alexander, Pepke-Zaba, Joanna, Konstantinides, Stavros V., Meyer, Guy, Bueno, Hector, Galié, Nazzareno, Gibbs, J. Simon R., Ageno, Walter, Agewall, Stefan, Almeida, Ana G., Andreotti, Felicita, Barbato, Emanuele, Baumbach, Andreas, Beygui, Farzin, Carlsen, Jørn, De Carlo, Marco, Delcroix, Marion, Subias, Pilar Escribano, Gaine, Sean, Goldhaber, Samuel Z., Gopalan, Deepa, Habib, Gilbert, Jenkins, David, Kjellström, Barbro, Lainscak, Mitja, Lee, Geraldine, Le Gal, Grégoire, Messas, Emmanuel, Morais, Joao, Piepoli, Massimo Francesco, Price, Susanna, Salvi, Aldo, Sanchez, Olivier, Stortecky, Stefan, Thielmann, Matthias, Noordegraaf, Anton Vonk, Becattini, Cecilia, Bueno, Héctor, Geersing, Geert Jan, Harjola, Veli Pekka, Huisman, Menno V., Humbert, Marc, Jennings, Catriona Sian, Jiménez, David, Kucher, Nils, Lang, Irene Marthe, Lankeit, Mareike, Lorusso, Roberto, Mazzolai, Lucia, Meneveau, Nicolas, Áinle, Fionnuala Ní, Prandoni, Paolo, Pruszczyk, Piotr, Righini, Marc, Torbicki, Adam, Van Belle, Eric, Zamorano, José Luis, Windecker, Stephan, Aboyans, Victor, Baigent, Colin, Collet, Jean Philippe, Dean, Veronica, Delgado, Victoria, Fitzsimons, Donna, Gale, Chris P., Grobbee, Diederick E., Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo A., Landmesser, Ulf, Leclercq, Christophe, Lettino, Maddalena, Lewis, Basil S., Merkely, Bela, Mueller, Christian, Petersen, Steffen E., Petronio, Anna Sonia, Richter, Dimitrios J., Roffi, Marco, Shlyakhto, Evgeny, Simpson, Iain A., Sousa-Uva, Miguel, Touyz, Rhian M., Hammoudi, Naima, Hayrapetyan, Hamlet, Mascherbauer, Julia, Ibrahimov, Firdovsi, Polonetsky, Oleg, Lancellotti, Patrizio, Tokmakova, Mariya, Skoric, Bosko, Michaloliakos, Ioannis, Hutyra, Martin, Mellemkjaer, Søren, Mansour, Mostafa, Reinmets, Julia, Jääskeläinen, Pertti, Angoulvant, Denis, Bauersachs, Johann, Giannakoulas, George, Zima, Endre, Vizza, Carmine Dario, Sugraliyev, Akhmetzhan, Bytyçi, Ibadete, Maca, Aija, Ereminiene, Egle, Huijnen, Steve, Xuereb, Robert, Diaconu, Nadejda, Bulatovic, Nebojsa, Asfalou, Ilyasse, Bosevski, Marijan, Halvorsen, Sigrun, Sobkowicz, Bozena, Ferreira, Daniel, Petris, Antoniu Octavian, Moiseeva, Olga, Zavatta, Marco, Obradovic, Slobodan, Šimkova, Iveta, Radsel, Peter, Ibanez, Borja, Wikström, Gerhard, Aujesky, Drahomir, Kaymaz, Cihangir, Parkhomenko, Alexander, and Pepke-Zaba, Joanna
Published: 2020

46. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)

Author: HAG Trombose, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Cancer, Global Health, Cardiovasculaire Epi Team 9, Konstantinides, Stavros V., Meyer, Guy, Bueno, Hector, Galié, Nazzareno, Gibbs, J. Simon R., Ageno, Walter, Agewall, Stefan, Almeida, Ana G., Andreotti, Felicita, Barbato, Emanuele, Baumbach, Andreas, Beygui, Farzin, Carlsen, Jørn, De Carlo, Marco, Delcroix, Marion, Subias, Pilar Escribano, Gaine, Sean, Goldhaber, Samuel Z., Gopalan, Deepa, Habib, Gilbert, Jenkins, David, Kjellström, Barbro, Lainscak, Mitja, Lee, Geraldine, Le Gal, Grégoire, Messas, Emmanuel, Morais, Joao, Piepoli, Massimo Francesco, Price, Susanna, Salvi, Aldo, Sanchez, Olivier, Stortecky, Stefan, Thielmann, Matthias, Noordegraaf, Anton Vonk, Becattini, Cecilia, Bueno, Héctor, Geersing, Geert Jan, Harjola, Veli Pekka, Huisman, Menno V., Humbert, Marc, Jennings, Catriona Sian, Jiménez, David, Kucher, Nils, Lang, Irene Marthe, Lankeit, Mareike, Lorusso, Roberto, Mazzolai, Lucia, Meneveau, Nicolas, Áinle, Fionnuala Ní, Prandoni, Paolo, Pruszczyk, Piotr, Righini, Marc, Torbicki, Adam, Van Belle, Eric, Zamorano, José Luis, Windecker, Stephan, Aboyans, Victor, Baigent, Colin, Collet, Jean Philippe, Dean, Veronica, Delgado, Victoria, Fitzsimons, Donna, Gale, Chris P., Grobbee, Diederick E., Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo A., Landmesser, Ulf, Leclercq, Christophe, Lettino, Maddalena, Lewis, Basil S., Merkely, Bela, Mueller, Christian, Petersen, Steffen E., Petronio, Anna Sonia, Richter, Dimitrios J., Roffi, Marco, Shlyakhto, Evgeny, Simpson, Iain A., Sousa-Uva, Miguel, Touyz, Rhian M., Hammoudi, Naima, Hayrapetyan, Hamlet, Mascherbauer, Julia, Ibrahimov, Firdovsi, Polonetsky, Oleg, Lancellotti, Patrizio, Tokmakova, Mariya, Skoric, Bosko, Michaloliakos, Ioannis, Hutyra, Martin, Mellemkjaer, Søren, Mansour, Mostafa, Reinmets, Julia, Jääskeläinen, Pertti, Angoulvant, Denis, Bauersachs, Johann, Giannakoulas, George, Zima, Endre, Vizza, Carmine Dario, Sugraliyev, Akhmetzhan, Bytyçi, Ibadete, Maca, Aija, Ereminiene, Egle, Huijnen, Steve, Xuereb, Robert, Diaconu, Nadejda, Bulatovic, Nebojsa, Asfalou, Ilyasse, Bosevski, Marijan, Halvorsen, Sigrun, Sobkowicz, Bozena, Ferreira, Daniel, Petris, Antoniu Octavian, Moiseeva, Olga, Zavatta, Marco, Obradovic, Slobodan, Šimkova, Iveta, Radsel, Peter, Ibanez, Borja, Wikström, Gerhard, Aujesky, Drahomir, Kaymaz, Cihangir, Parkhomenko, Alexander, Pepke-Zaba, Joanna, HAG Trombose, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Cancer, Global Health, Cardiovasculaire Epi Team 9, Konstantinides, Stavros V., Meyer, Guy, Bueno, Hector, Galié, Nazzareno, Gibbs, J. Simon R., Ageno, Walter, Agewall, Stefan, Almeida, Ana G., Andreotti, Felicita, Barbato, Emanuele, Baumbach, Andreas, Beygui, Farzin, Carlsen, Jørn, De Carlo, Marco, Delcroix, Marion, Subias, Pilar Escribano, Gaine, Sean, Goldhaber, Samuel Z., Gopalan, Deepa, Habib, Gilbert, Jenkins, David, Kjellström, Barbro, Lainscak, Mitja, Lee, Geraldine, Le Gal, Grégoire, Messas, Emmanuel, Morais, Joao, Piepoli, Massimo Francesco, Price, Susanna, Salvi, Aldo, Sanchez, Olivier, Stortecky, Stefan, Thielmann, Matthias, Noordegraaf, Anton Vonk, Becattini, Cecilia, Bueno, Héctor, Geersing, Geert Jan, Harjola, Veli Pekka, Huisman, Menno V., Humbert, Marc, Jennings, Catriona Sian, Jiménez, David, Kucher, Nils, Lang, Irene Marthe, Lankeit, Mareike, Lorusso, Roberto, Mazzolai, Lucia, Meneveau, Nicolas, Áinle, Fionnuala Ní, Prandoni, Paolo, Pruszczyk, Piotr, Righini, Marc, Torbicki, Adam, Van Belle, Eric, Zamorano, José Luis, Windecker, Stephan, Aboyans, Victor, Baigent, Colin, Collet, Jean Philippe, Dean, Veronica, Delgado, Victoria, Fitzsimons, Donna, Gale, Chris P., Grobbee, Diederick E., Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo A., Landmesser, Ulf, Leclercq, Christophe, Lettino, Maddalena, Lewis, Basil S., Merkely, Bela, Mueller, Christian, Petersen, Steffen E., Petronio, Anna Sonia, Richter, Dimitrios J., Roffi, Marco, Shlyakhto, Evgeny, Simpson, Iain A., Sousa-Uva, Miguel, Touyz, Rhian M., Hammoudi, Naima, Hayrapetyan, Hamlet, Mascherbauer, Julia, Ibrahimov, Firdovsi, Polonetsky, Oleg, Lancellotti, Patrizio, Tokmakova, Mariya, Skoric, Bosko, Michaloliakos, Ioannis, Hutyra, Martin, Mellemkjaer, Søren, Mansour, Mostafa, Reinmets, Julia, Jääskeläinen, Pertti, Angoulvant, Denis, Bauersachs, Johann, Giannakoulas, George, Zima, Endre, Vizza, Carmine Dario, Sugraliyev, Akhmetzhan, Bytyçi, Ibadete, Maca, Aija, Ereminiene, Egle, Huijnen, Steve, Xuereb, Robert, Diaconu, Nadejda, Bulatovic, Nebojsa, Asfalou, Ilyasse, Bosevski, Marijan, Halvorsen, Sigrun, Sobkowicz, Bozena, Ferreira, Daniel, Petris, Antoniu Octavian, Moiseeva, Olga, Zavatta, Marco, Obradovic, Slobodan, Šimkova, Iveta, Radsel, Peter, Ibanez, Borja, Wikström, Gerhard, Aujesky, Drahomir, Kaymaz, Cihangir, Parkhomenko, Alexander, and Pepke-Zaba, Joanna
Published: 2020

47. Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves

Author: Bleiziffer, Sabine, Simonato, Matheus, Webb, John G., Rodes-Cabau, Josep, Pibarot, Philippe, Kornowski, Ran, Windecker, Stephan, Erlebach, Magdalena, Duncan, Alison, Seiffert, Moritz, Unbehaun, Axel, Frerker, Christian, Conzelmann, Lars, Wijeysundera, Harindra, Kim, Won-Keun, Montorfano, Matteo, Latib, Azeem, Tchetche, Didier, Allali, Abdelhakim, Abdel-Wahab, Mohamed, Orvin, Katia, Stortecky, Stefan, Nissen, Henrik, Holzamer, Andreas, Urena, Marina, Testa, Luca, Agrifoglio, Marco, Whisenant, Brian, Sathananthan, Janarthanan, Napodano, Massimo, Landi, Antonio, Fiorina, Claudia, Zittermann, Armin, Veulemans, Verena, Sinning, Jan-Malte, Saia, Francesco, Brecker, Stephen, Presbitero, Patrizia, De Backer, Ole, Sondergaard, Lars, Bruschi, Giuseppe, Franco, Luis Nombela, Petronio, Anna Sonia, Barbanti, Marco, Cerillo, Alfredo, Spargias, Konstantinos, Schofer, Joachim, Cohen, Mauricio, Munoz-Garcia, Antonio, Finkelstein, Ariel, Adam, Matti, Serra, Vicenc, Teles, Rui Campante, Champagnac, Didier, Iadanza, Alessandro, Chodor, Piotr, Eggebrecht, Holger, Welsh, Robert, Caixeta, Adriano, Salizzoni, Stefano, Dager, Antonio, Auffret, Vincent, Cheema, Asim, Ubben, Timm, Ancona, Marco, Rudolph, Tanja, Gummert, Jan, Tseng, Elaine, Noble, Stephane, Bunc, Matjaz, Roberts, David, Kass, Malek, Gupta, Anuj, Leon, Martin B., Dvir, Danny, Bleiziffer, Sabine, Simonato, Matheus, Webb, John G., Rodes-Cabau, Josep, Pibarot, Philippe, Kornowski, Ran, Windecker, Stephan, Erlebach, Magdalena, Duncan, Alison, Seiffert, Moritz, Unbehaun, Axel, Frerker, Christian, Conzelmann, Lars, Wijeysundera, Harindra, Kim, Won-Keun, Montorfano, Matteo, Latib, Azeem, Tchetche, Didier, Allali, Abdelhakim, Abdel-Wahab, Mohamed, Orvin, Katia, Stortecky, Stefan, Nissen, Henrik, Holzamer, Andreas, Urena, Marina, Testa, Luca, Agrifoglio, Marco, Whisenant, Brian, Sathananthan, Janarthanan, Napodano, Massimo, Landi, Antonio, Fiorina, Claudia, Zittermann, Armin, Veulemans, Verena, Sinning, Jan-Malte, Saia, Francesco, Brecker, Stephen, Presbitero, Patrizia, De Backer, Ole, Sondergaard, Lars, Bruschi, Giuseppe, Franco, Luis Nombela, Petronio, Anna Sonia, Barbanti, Marco, Cerillo, Alfredo, Spargias, Konstantinos, Schofer, Joachim, Cohen, Mauricio, Munoz-Garcia, Antonio, Finkelstein, Ariel, Adam, Matti, Serra, Vicenc, Teles, Rui Campante, Champagnac, Didier, Iadanza, Alessandro, Chodor, Piotr, Eggebrecht, Holger, Welsh, Robert, Caixeta, Adriano, Salizzoni, Stefano, Dager, Antonio, Auffret, Vincent, Cheema, Asim, Ubben, Timm, Ancona, Marco, Rudolph, Tanja, Gummert, Jan, Tseng, Elaine, Noble, Stephane, Bunc, Matjaz, Roberts, David, Kass, Malek, Gupta, Anuj, Leon, Martin B., and Dvir, Danny
Abstract: Aims Due to bioprosthetic valve degeneration, aortic valve-in-valve (ViV) procedures are increasingly performed. There are no data on long-term outcomes after aortic ViV. Our aim was to perform a large-scale assessment of long-term survival and reintervention after aortic ViV. Methods and results A total of 1006 aortic ViV procedures performed more than 5 years ago [mean age 77.7 +/- 9.7 years; 58.8% mate; median STS-PROM score 7.3% (4.2-12.0)] were included in the analysis. Patients were treated with Medtronic self-expandable valves (CoreVatve/Evolut, Medtronic Inc., Minneapolis, MN, USA) (n = 523, 52.0%), Edwards balloo-nexpandable valves (EBEV, SAPIEN/SAPIEN XT/SAPIEN 3, Edwards Lifesciences, Irvine, CA, USA) (n=435, 43.2%), and other devices (n =48, 4.8%). Survival was tower at 8 years in patients with small-failed bioprostheses [internal diameter (ID) < 20 mm] compared with those with large-failed bioprostheses (ID > 20 mm) (33.2% vs. 40.5%, P= 0.01). Independent correlates for mortality included smaller-failed bioprosthetic valves [hazard ratio (HR) 1.07 (95% confidence interval (CI) 1.02-1.13)], age [HR 1.21 (95% CI 1.01-1.45)], and non-transfemoral access [HR 1.43 (95% CI 1.11-1.84)]. There were 40 reinterventions after ViV. Independent correlates for all-cause reintervention included pre-existing severe prosthesis-patient mismatch [subhazard ratio (SHR) 4.34 (95% CI 1.31-14.39)], device malposition [SHR 3.75 (95% CI 1.36-10.35)], EBEV [SHR 3.34 (95% CI 1.26-8.85)], and age [SHR 0.59 (95% CI 0.44-0.78)]. Conclusions: The size of the original failed valve may influence long-term mortality, and the type of the transcatheter valve may influence the need for reintervention after aortic ViV. [GRAPHICS] .
Published: 2020

48. Transcatheter Aortic Valve Replacement With the LOTUS Edge System: Early European Experience

Author: Armario, Xavier, Rosseel, Liesbeth, Kharbanda, Rajesh, Khogali, Saib, Abdel-Wahab, Mohamed, Van Mieghem, Nicolas, Tchetche, Didier, Dumonteil, Nicolas, De Backer, Ole, Cotton, James, McGrath, Brian, Balakrishnan, Deepu, Ali, Noman, Farhan, Serdar, Joseph, Jubin, Charbonnier, Gaetan, Okuno, Taishi, McHugh, Fiachra, Hildick-Smith, David, Gilgen, Nicole, Frerker, Christian, Angelillis, Marco, Grygier, Marek, Cockburn, James, Bjursten, Henrik, Teles, Rui, Petronio, Anna Sonia, Pilgrim, Thomas, Sinning, Jan-Malte, Nickenig, Georg, Sondergaard, Lars, Mylotte, Darren, Armario, Xavier, Rosseel, Liesbeth, Kharbanda, Rajesh, Khogali, Saib, Abdel-Wahab, Mohamed, Van Mieghem, Nicolas, Tchetche, Didier, Dumonteil, Nicolas, De Backer, Ole, Cotton, James, McGrath, Brian, Balakrishnan, Deepu, Ali, Noman, Farhan, Serdar, Joseph, Jubin, Charbonnier, Gaetan, Okuno, Taishi, McHugh, Fiachra, Hildick-Smith, David, Gilgen, Nicole, Frerker, Christian, Angelillis, Marco, Grygier, Marek, Cockburn, James, Bjursten, Henrik, Teles, Rui, Petronio, Anna Sonia, Pilgrim, Thomas, Sinning, Jan-Malte, Nickenig, Georg, Sondergaard, Lars, and Mylotte, Darren
Published: 2020

49. Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves

Author: Bleiziffer, Sabine, Simonato, Matheus, Webb, John G., Rodés-Cabau, Josep, Pibarot, Philippe, Kornowski, Ran, Windecker, Stephan, Erlebach, Magdalena, Duncan, Alison, Seiffert, Moritz, Unbehaun, Axel, Frerker, Christian, Conzelmann, Lars, Wijeysundera, Harindra, Kim, Won Keun, Montorfano, Matteo, Latib, Azeem, Tchetche, Didier, Allali, Abdelhakim, Abdel-Wahab, Mohamed, Orvin, Katia, Stortecky, Stefan, Nissen, Henrik, Holzamer, Andreas, Urena, Marina, Testa, Luca, Agrifoglio, Marco, Whisenant, Brian, Sathananthan, Janarthanan, Napodano, Massimo, Landi, Antonio, Fiorina, Claudia, Zittermann, Armin, Veulemans, Verena, Sinning, Jan Malte, Saia, Francesco, Brecker, Stephen, Presbitero, Patrizia, de Backer, Ole, Søndergaard, Lars, Bruschi, Giuseppe, Franco, Luis Nombela, Petronio, Anna Sonia, Barbanti, Marco, Cerillo, Alfredo, Spargias, Konstantinos, Schofer, Joachim, Cohen, Mauricio, Muñoz-Garcia, Antonio, Finkelstein, Ariel, Adam, Matti, Serra, Vicenç, Teles, Rui Campante, Champagnac, Didier, Iadanza, Alessandro, Chodor, Piotr, Eggebrecht, Holger, Welsh, Robert, Caixeta, Adriano, Salizzoni, Stefano, Dager, Antonio, Auffret, Vincent, Cheema, Asim, Ubben, Timm, Ancona, Marco, Rudolph, Tanja, Gummert, Jan, Tseng, Elaine, Noble, Stephane, Bunc, Matjaz, Roberts, David, Kass, Malek, Gupta, Anuj, Leon, Martin B., Dvir, Danny, Bleiziffer, Sabine, Simonato, Matheus, Webb, John G., Rodés-Cabau, Josep, Pibarot, Philippe, Kornowski, Ran, Windecker, Stephan, Erlebach, Magdalena, Duncan, Alison, Seiffert, Moritz, Unbehaun, Axel, Frerker, Christian, Conzelmann, Lars, Wijeysundera, Harindra, Kim, Won Keun, Montorfano, Matteo, Latib, Azeem, Tchetche, Didier, Allali, Abdelhakim, Abdel-Wahab, Mohamed, Orvin, Katia, Stortecky, Stefan, Nissen, Henrik, Holzamer, Andreas, Urena, Marina, Testa, Luca, Agrifoglio, Marco, Whisenant, Brian, Sathananthan, Janarthanan, Napodano, Massimo, Landi, Antonio, Fiorina, Claudia, Zittermann, Armin, Veulemans, Verena, Sinning, Jan Malte, Saia, Francesco, Brecker, Stephen, Presbitero, Patrizia, de Backer, Ole, Søndergaard, Lars, Bruschi, Giuseppe, Franco, Luis Nombela, Petronio, Anna Sonia, Barbanti, Marco, Cerillo, Alfredo, Spargias, Konstantinos, Schofer, Joachim, Cohen, Mauricio, Muñoz-Garcia, Antonio, Finkelstein, Ariel, Adam, Matti, Serra, Vicenç, Teles, Rui Campante, Champagnac, Didier, Iadanza, Alessandro, Chodor, Piotr, Eggebrecht, Holger, Welsh, Robert, Caixeta, Adriano, Salizzoni, Stefano, Dager, Antonio, Auffret, Vincent, Cheema, Asim, Ubben, Timm, Ancona, Marco, Rudolph, Tanja, Gummert, Jan, Tseng, Elaine, Noble, Stephane, Bunc, Matjaz, Roberts, David, Kass, Malek, Gupta, Anuj, Leon, Martin B., and Dvir, Danny
Abstract: Aims Due to bioprosthetic valve degeneration, aortic valve-in-valve (ViV) procedures are increasingly performed. There are no data on long-term outcomes after aortic ViV. Our aim was to perform a large-scale assessment of long-term survival and reintervention after aortic ViV. Methods A total of 1006 aortic ViV procedures performed more than 5 years ago [mean age 77.7 ± 9.7 years; 58.8% male; and results median STS-PROM score 7.3% (4.2-12.0)] were included in the analysis. Patients were treated with Medtronic self-expandable valves (CoreValve/Evolut, Medtronic Inc., Minneapolis, MN, USA) (n = 523, 52.0%), Edwards balloon-expandable valves (EBEV, SAPIEN/SAPIEN XT/SAPIEN 3, Edwards Lifesciences, Irvine, CA, USA) (n = 435, 43.2%), and other devices (n = 48, 4.8%). Survival was lower at 8 years in patients with small-failed bioprostheses [internal diameter (ID) <_ 20 mm] compared with those with large-failed bioprostheses (ID > 20 mm) (33.2% vs. 40.5%, P = 0.01). Independent correlates for mortality included smaller-failed bioprosthetic valves [hazard ratio (HR) 1.07 (95% confidence interval (CI) 1.02-1.13)], age [HR 1.21 (95% CI 1.01-1.45)], and non-transfemoral access [HR 1.43 (95% CI 1.11-1.84)]. There were 40 reinterventions after ViV. Independent correlates for all-cause reintervention included pre-existing severe prosthesis-patient mismatch [subhazard ratio (SHR) 4.34 (95% CI 1.31-14.39)], device malposition [SHR 3.75 (95% CI 1.36-10.35)], EBEV [SHR 3.34 (95% CI 1.26-8.85)], and age [SHR 0.59 (95% CI 0.44-0.78)]. Conclusions The size of the original failed valve may influence long-term mortality, and the type of the transcatheter valve may influence the need for reintervention after aortic ViV.
Published: 2020

50. Bicuspid aortic valve sizing for transcatheter aortic valve implantation:Development and validation of an algorithm based on multi-slice computed tomography

Author: Petronio, Anna S., Angelillis, Marco, De Backer, Ole, Giannini, Cristina, Costa, Giulia, Fiorina, Claudia, Castriota, Fausto, Bedogni, Francesco, Laborde, Jean C., Søndergaard, Lars, Petronio, Anna S., Angelillis, Marco, De Backer, Ole, Giannini, Cristina, Costa, Giulia, Fiorina, Claudia, Castriota, Fausto, Bedogni, Francesco, Laborde, Jean C., and Søndergaard, Lars
Abstract: Background: No indication are available for transcatheter aortic valve implantation (TAVI) sizing in bicuspid aortic valve (BAV). Aim of the study is to develop and validate a Multi-Slice Computed Tomography (MSCT)-based algorithm for transcatheter heart valve (THV) sizing in patients with stenotic BAV under evaluation for TAVI. Methods: A two steps method was applied: 1)evaluation of a cohort of 19 consecutive patients with type I BAV stenosis undergoing TAVI through pre and post-procedural MSCT, and development of an algorithm for THV sizing; 2)validation of the algorithm on a new cohort of 21 patients. Results: In the first cohort, a high correlation was found between the raphe-level area measured at pre-procedural MSCT and the smallest THV area measured at post-procedural MSCT (p < 0.001). Moreover, reduced THV expansion was observed among patients with higher calcium burden (p = 0.048). Then, a new algorithm for TAVI sizing in BAV was develop (CASPER: Calcium Algorithm Sizing for bicusPid Evaluation with Raphe). This algorithm is based on the reassessment of the perimeter/area derived annulus diameter, according to three main anatomical features: 1) the ratio between raphe length and annulus diameter; 2)calcium burden; 3)calcium distribution in relation to the raphe. The algorithm was then validated in a new cohort of 21 patients, achieving 100% of procedural success and excellent TAVI performance. Conclusion: MSCT assessment of raphe length, calcium burden and its distribution is of crucial relevance in the pre-procedural evaluation of patients with BAV. These anatomical features can be combined in a new and simple algorithm for TAVI sizing.
Published: 2020

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Publication Year Range

Publication Type

Database

Publisher

63 results on '"Petronio Anna"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources